[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 219
1. Theisen J, Feith M, Stein HJ, Siewert JR: Management of early esophageal cancer. Adv Surg; 2007;41:229-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In early esophageal cancer, squamous cell cancer and early adenocarcinoma must be managed differently because they have different origins, pathogenesis. and clinical characteristics.
  • Instead, an individualized strategy should be based on the depth of tumor infiltration into the mucosa or submucosa, the presence or absence of lymph node metastases, the multicentricity of tumor growth, the length of the segment of intestinal metaplasia, and comorbidities of the patient.
  • Limited resection with jejunal interposition provides an effective treatment option for patients who have early esophageal adenocarcinoma.
  • The onset of lymph node involvement is later in patients who have early adenocarcinoma than in patients who have squamous cell cancer, probably because chronic injury and repair mechanisms obliterate the otherwise abundant lymph vessels.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972568.001).
  • [ISSN] 0065-3411
  • [Journal-full-title] Advances in surgery
  • [ISO-abbreviation] Adv Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


2. Maru DM: Barrett's esophagus: diagnostic challenges and recent developments. Ann Diagn Pathol; 2009 Jun;13(3):212-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion of histologic classification into the risk assessment of adenocarcinoma arising from Barrett's esophagus (BE) has placed surgical pathologist in the center of clinical care and research endeavors.
  • Recent advances in endoscopic diagnostic and therapeutic modalities demand additional proficiency in diagnosis and grading of dysplasia.
  • (1) Discuss the definition of BE and features differentiating BE vs intestinal metaplasia involving cardia. (2) Describe the morphological approach of diagnosing and grading of dysplasia and differentiation of high-grade dysplasia from intramucosal carcinoma. (3) Role of special stains in diagnosis of BE and dysplasia. (4) Brief review the literature on histologic and endoscopic factors associated with progression of BE to adenocarcinoma. (5) Discuss the biomarkers in progression of BE to adenocarcinoma.
  • Because of the controversy in defining BE, the histologic type of columnar mucosa and presence or absence of intestinal metaplasia should be specified in pathology report.
  • The extent of high-grade dysplasia, high-grade dysplasia with certain endoscopic abnormalities, and low-grade dysplasia, when diagnosed with consensus by 2 or 3 gastrointestinal pathologists, has higher risk of progression to adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Precancerous Conditions / diagnosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433303.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


3. Inadomi JM: Surveillance in Barrett's esophagus: a failed premise. Keio J Med; 2009 Mar;58(1):12-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective case-control study was performed to determine whether surveillance endoscopy prolonged survival in a cohort of U.S. veterans diagnosed with esophageal adenocarcinoma.
  • Cost-effectiveness analysis was employed to compare competing strategies of management for patients with Barrett's esophagus to determine whether surveillance strategies using alternative biomarkers could out-perform dysplasia based surveillance, and whether new techniques for eradicating Barrett's metaplasia would constitute cost-effective strategies.
  • RESULTS: Surveillance did not improve long-term survival among veterans diagnosed with esophageal adenocarcinoma.
  • If a biomarker were developed whose sensitivity and specificity to predict cancer development exceeded 80%, this could represent a more viable strategy than dysplasia-based surveillance and overcome the inherent inter- and intra-observer variations in dysplasia diagnosis that currently limit the effectiveness of surveillance programs.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / economics. Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Biomarkers, Tumor / metabolism. Humans. Practice Guidelines as Topic. Risk Factors


Advertisement
4. Ajumobi A, Bahjri K, Jackson C, Griffin R: Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci; 2010 Jun;55(6):1615-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surveillance endoscopy (SE) is recommended in order to detect and treat high-grade dysplasia and esophageal adenocarcinoma early and prevent deaths.
  • Two patients were excluded from the final analysis: one had an esophagectomy after an index diagnosis of high-grade dysplasia, and one had a diagnosis of esophageal adenocarcinoma 2 days after an initial impression of Barrett's esophagus.
  • There were 165 patients with Barrett's metaplasia or dysplasia who had SE more than once and were included in the final analysis.
  • None (0/165, 0%) progressed to esophageal adenocarcinoma; 3.6% (6/165) progressed to high-grade dysplasia and 11.5% (19/165) regressed to normal mucosa.
  • Four patients regressed to normal mucosa, one progressed to high-grade dysplasia and none progressed to esophageal adenocarcinoma.
  • None progressed to esophageal adenocarcinoma or high-grade dysplasia but three regressed to normal mucosa.
  • Veteran patients with Barrett's esophagus undergoing SE rarely progress to high-grade dysplasia or esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Esophagoscopy. Mass Screening / methods. Precancerous Conditions / diagnosis


5. Moretó M: Diagnosis of esophagogastric tumors. Endoscopy; 2005 Jan;37(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of esophagogastric tumors.
  • 2) Intestinal metaplasia types II and III have been shown to have a higher rate of progression to low-grade dysplasia than type I.
  • 5) High-resolution endoscopy allows more precise diagnosis of early gastric cancer.
  • 7) Gastric adenocarcinoma was found to show specific changes in the fluorescence spectra emitted, in comparison with normal gastric mucosa.
  • [MeSH-major] Endoscopy, Digestive System. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657854.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


6. Domagała-Kulawik J, Górnicka B, Krenke R, Mich S, Chazan R: The value of cytological diagnosis of small cell lung carcinoma. Pneumonol Alergol Pol; 2010;78(3):203-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of cytological diagnosis of small cell lung carcinoma.
  • Accurate and quick diagnosis is crucial to initiate proper treatment.
  • The aim of this study was to establish the value of initial cytological diagnosis and to present typical cytological features of SCLC.
  • RESULTS: In 77% of SCLC cases, the diagnosis was established only by cytology; in 23% of cases, both cytological and histological recognition was possible.
  • The morphology of SCLC cells was not uniform, and often a mixture of non-small atypical cells and bronchial epithelial cells with signs of metaplasia was observed.
  • There were four cases of combined cell type with large cell carcinoma and two with adenocarcinoma.
  • CONCLUSION: Diagnosis of SCLC in cytological smears is accurate, and final diagnosis is based on light microscopy.
  • In the differential diagnosis, other tumours of small cells have to be taken into account.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle / methods. Bronchoalveolar Lavage Fluid / chemistry. Cytodiagnosis / methods. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pleural Effusion, Malignant / chemistry. Poland. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461688.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Da CL, Xin Y, Zhao J, Luo XD: Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol; 2009 Aug 28;15(32):4055-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The PV9000 immunohistochemical method was used to detect the expression of YAP and survivin in 98 cases of normal gastric mucosa, 58 intestinal metaplasia (IM), 32 dysplasia and 98 gastric carcinoma.
  • Survivin expression gradually increased from 41.7% in well differentiated adenocarcinoma through 58.3% in moderately differentiated adenocarcinoma to 75.6% in poorly differentiated adenocarcinoma, with significant Rank correlation, r(k) = 0.279, P < 0.01.
  • Detecting both markers together may help in early diagnosis of gastric carcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Aged. Apoptosis. Female. Gastric Mucosa. Gene Expression Profiling. Humans. Inhibitor of Apoptosis Proteins. Intestines / metabolism. Lymphatic Metastasis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1999 Dec;23(4):387-8 [10581018.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 19;384(1):114-9 [19393221.001]
  • [Cites] Acta Obstet Gynecol Scand. 2002 Feb;81(2):162-7 [11942908.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):11-23 [12535517.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2145-52 [8035999.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Biochemistry. 2005 Jan 11;44(1):11-7 [15628841.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Prostate. 2005 Aug 1;64(3):293-302 [15754318.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 19;334(1):207-12 [15993841.001]
  • [Cites] Cell. 2006 Jan 27;124(2):267-73 [16439203.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1483-93 [16407408.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2337-47 [16985068.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1120-33 [17889654.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):103-9 [18175224.001]
  • [Cites] Mol Cell. 2008 Dec 26;32(6):803-14 [19111660.001]
  • [Cites] Biochem Cell Biol. 2009 Feb;87(1):77-91 [19234525.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):44-53 [11925104.001]
  • (PMID = 19705503.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Phosphoproteins; 0 / YAP1 (Yes-associated) protein, human
  • [Other-IDs] NLM/ PMC2731958
  •  go-up   go-down


8. Arra A, Nieva NB, Rey N, Fernández AO: [Cytokeratin 7 and 20 in Barrett's esophagus]. Rev Fac Cien Med Univ Nac Cordoba; 2005;62(3):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus (BE) has been identified as the most important risk factor for adenocarcinoma of the distal esophagus.
  • Intestinal metaplasia may also develop in gastric mucosa (IMG) at the gastroesophageal junction.
  • Moreover, these conditions are difficult to distinguish one from another only based on endoscopic and morphologic criteria.
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Metaplasia. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972735.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


9. Goto Y, Ando T, Nishio K, Kawai S, Ishida Y, Naito M, Goto H, Hamajima N: Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int J Med Sci; 2007;4(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A single nucleotide polymorphism at intron 2 of Gab1 (JST164345) was examined for 454 Japanese health checkup examinees (126 males and 328 females) aged 35 to 85 without a history of gastric cancer and 202 gastric cancer patients (134 males and 68 females) aged 33 to 94 with pathologically confirmed diagnosis of gastric adenocarcinoma.
  • Compared to gastric cancer case, the Gab1 did not influence the step of atrophy/metaplasia-gastric cancer sequence.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Female. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Male. Metaplasia. Middle Aged. Odds Ratio. Protein Phosphatase 2. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / genetics. Protein Tyrosine Phosphatases / metabolism. Risk Factors. SH2 Domain-Containing Protein Tyrosine Phosphatases. Stomach Neoplasms / etiology. src Homology Domains

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):299-307 [10752981.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13842-8 [10788507.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):703-6 [11533078.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):24380-7 [11323411.001]
  • [Cites] Jpn J Cancer Res. 2001 Apr;92(4):383-9 [11346459.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):865-8 [11011111.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8513-25 [11046147.001]
  • [Cites] J Cell Biol. 2000 Jun 26;149(7):1419-32 [10871282.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):294-9 [11843961.001]
  • [Cites] FEBS Lett. 2002 Mar 27;515(1-3):1-7 [11943184.001]
  • [Cites] Int J Mol Med. 2002 Sep;10(3):321-6 [12165808.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1546-56 [12629518.001]
  • [Cites] Microbes Infect. 2003 Feb;5(2):143-50 [12650772.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1691-708 [12686619.001]
  • [Cites] Gastric Cancer. 2003;6(4):230-6 [14716517.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2007-15 [15026337.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):203-8 [16032704.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1809-16 [10068651.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16643-6 [9642214.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1189-202 [8622663.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1611-4 [7681217.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1607-11 [8096088.001]
  • (PMID = 17211494.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GAB1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC1752235
  •  go-up   go-down


10. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue CA, Maitra A, Ashfaq R, Hustinx S, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD, Montgomery E: Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):281-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
  • Intestinal metaplasia and gastric epithelial dysplasia are precursor lesions to gastric adenocarcinoma, but are not readily detectable clinically, radiographically, or endoscopically.
  • In search of such markers, tissue microarrays were prepared for 133 patients of resected gastric adenocarcinoma.
  • Tissue microarrays contained primary cancer, normal stomach, intestinal metaplasia, and gastric epithelial dysplasia and were probed with antibodies against nine potential markers that were either identified in a database of genes overexpressed in gastric adenocarcinoma or were already of interest to our laboratory: claudin-4, mitogen-activated protein kinase kinase 4 (MKK4), 14-3-3sigma (stratifin), S100A4, mesothelin, fascin, topoisomerase IIalpha, HER-2/neu, and epithelial growth factor receptor.
  • Three markers discriminated gastric adenocarcinoma precursor lesions from normal gastric mucosa.
  • Claudin-4 expression was present in 36 intestinal metaplasia lesions (100%) and 14 gastric epithelial dysplasia lesions (100%), but in only 16 normal stomach samples (15%).
  • MKK4 expression was present in 24 intestinal metaplasia lesions (89%) and 12 gastric epithelial dysplasia lesions (100%), but in only 6 normal stomach samples (8%).
  • Stratifin expression was present in 29 intestinal metaplasia lesions (97%) and 8 gastric epithelial dysplasia lesions (100%), but in only 2 normal stomach samples (3%).
  • Sensitivity and specificity for detection of the precursor lesion intestinal metaplasia were 100% and 85%, respectively, for claudin-4; 89% and 92%, respectively, for MKK4; and 97% and 97%, respectively, for stratifin.
  • In conclusion, claudin-4, MKK4, and stratifin immunolabeling detects precursor lesions of gastric adenocarcinoma that are otherwise clinically, radiographically, and endoscopically inapparent.
  • These findings may prove useful in the diagnosis and therapeutic targeting of gastric adenocarcinoma precursor lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Exonucleases / biosynthesis. MAP Kinase Kinase 4 / biosynthesis. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Aged. Claudin-4. Exoribonucleases. Female. Gene Expression. Humans. Immunohistochemistry. Male. Metaplasia / pathology. Microarray Analysis. Tissue Array Analysis


11. Quinlan JM, Colleypriest BJ, Farrant M, Tosh D: Epithelial metaplasia and the development of cancer. Biochim Biophys Acta; 2007 Sep;1776(1):10-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial metaplasia and the development of cancer.
  • Metaplasia means the conversion, in postnatal life, of one cell type to another.
  • Understanding the steps leading to metaplasia is important for two reasons.
  • Secondly, metaplasia predisposes to certain forms of neoplasia.
  • So understanding the molecular and cellular mechanisms underlying metaplasia will provide insights into clinical diagnosis and potential therapies.
  • One of the best-described examples of metaplasia is Barrett's metaplasia or the appearance of intestinal-like columnar tissue in the oesophagus.
  • Barrett's metaplasia develops as a result of gastro-oesophageal reflux and is considered the precursor lesion for oesophageal adenocarcinoma.
  • While we know quite a bit about the molecular events associated with the development of oesophageal adenocarcinoma, our understanding of the initial events leading to Barrett's metaplasia is lacking.
  • In the present review we will focus on examples of metaplasia that lead to neoplasia and discuss some of the underlying molecular and cellular mechanisms.
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / pathology. Humans. Metaplasia

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618050.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300415; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 137
  •  go-up   go-down


12. Maezato K, Nishimaki T, Oshiro M, Yamashiro T, Sasaki H, Sashida Y: Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today; 2007;37(12):1096-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the most superficial part of the tumor center contained a region of Barrett's mucosa with incomplete-type intestinal metaplasia and a well-differentiated adenocarcinoma component with goblet cells.
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Esophagectomy. Fatal Outcome. Humans. Male


13. Micev M, Cosić-Micev M: [Pathology and pathobiology of the oesophageal carcinoma]. Acta Chir Iugosl; 2010;57(2):15-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Barrett's esophagus is a precursor to esophageal adenocarcinoma and have a well described sequence of carcinogenesis: the Barrett's metaplasia-dysplasia-adenocarcinoma sequence, not all patients with this disorder require intensive surveillance.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Barrett Esophagus / complications. Barrett Esophagus / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Humans

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20954310.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  •  go-up   go-down


14. Younes M, Ertan A, Ergun G, Verm R, Bridges M, Woods K, Meriano F, Schmulen AC, Colman R, Johnson C, Barroso A, Schwartz J, McKechnie J, Lechago J: Goblet cell mimickers in esophageal biopsies are not associated with an increased risk for dysplasia. Arch Pathol Lab Med; 2007 Apr;131(4):571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Identification of intestinal-type goblet cells (ITGCs) in hematoxylin-eosin-stained sections of esophageal biopsies is essential for the diagnosis of Barrett metaplasia.
  • However, we have seen cases diagnosed as Barrett metaplasia based solely on cells that pose morphologic similarity to ITGCs on hematoxylin-eosin staining or stain positive with Alcian blue.
  • DESIGN: Initial biopsies from 78 patients with original diagnosis of Barrett metaplasia negative for dysplasia and a mean follow-up of 72 months were reviewed and reclassified into 3 categories:.
  • CONCLUSIONS: Our results indicate that the diagnosis of Barrett metaplasia should be rendered with confidence only when ITGCs are identified on routine hematoxylin-eosin-stained sections.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy. Disease Progression. Endoscopy, Digestive System. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425386.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA81570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Kuester D, El-Rifai W, Peng D, Ruemmele P, Kroeckel I, Peters B, Moskaluk CA, Stolte M, Mönkemüller K, Meyer F, Schulz HU, Hartmann A, Roessner A, Schneider-Stock R: Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus. Cancer Lett; 2009 Mar 08;275(1):117-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.
  • Hypermethylation was detected in 78.9% of esophageal adenocarcinomas, in 100% of Barrett's intraepithelial neoplasia, in 88.9% of Barrett's metaplasia, but only in 21.4% of normal esophageal mucosa samples (P<0.001) and correlated significantly with downregulation of MGMT transcripts (P=0.048) and protein expression (P=0.02).
  • High prevalence of MGMT hypermethylation may represent a candidate marker for improved diagnosis and targeted therapy in Barrett's adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Carcinoma / metabolism. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Gene Silencing. Metaplasia / metabolism. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 2003 Jan;36(1):23-31 [12503076.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4061-4 [12124342.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):223-7 [12538473.001]
  • [Cites] Cancer Lett. 2003 Feb 20;190(2):125-33 [12565166.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):521-9 [12592365.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1039-44 [12807758.001]
  • [Cites] Gastric Cancer. 2003;6(2):86-95 [12861399.001]
  • [Cites] Adv Exp Med Biol. 2003;532:39-49 [12908548.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):518-23 [12920593.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5306-12 [14614014.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] Dig Dis. 2004;22(2):126-33 [15383753.001]
  • [Cites] Carcinogenesis. 1983 Dec;4(12):1591-7 [6360407.001]
  • [Cites] Cancer Commun. 1990;2(1):13-20 [2369549.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7908-11 [2253230.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4131-4 [1868433.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):337-40 [1738185.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2255-7 [7554086.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):90-8 [10078936.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1493-500 [15870861.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):354-63 [15915369.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Hematol. 2006 May;83(4):341-7 [16757436.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):264-8 [16477636.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8952-9 [17875738.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Int J Oncol. 2001 Jun;18(6):1187-93 [11351250.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):805-9 [11519041.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8113-7 [11719438.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2760-8 [11753949.001]
  • [Cites] Jpn J Cancer Res. 2002 Feb;93(2):184-9 [11856482.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):37-44 [12517538.001]
  • (PMID = 19027227.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK067629; United States / NCI NIH HHS / CA / R01 CA106176; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ NIHMS576423; NLM/ PMC4028828
  •  go-up   go-down


16. Shigehara K, Taya T, Hisazumi H: Primary adenocarcinoma in the bladder diverticulum. Scand J Urol Nephrol; 2008;42(5):481-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma in the bladder diverticulum.
  • A transurethral resection was performed and histopathological examination revealed adenocarcinoma.
  • One month later, partial cystectomy was performed and histopathological examination indicated goblet cell metaplasia without residual tumor cells.
  • [MeSH-major] Adenocarcinoma / pathology. Diverticulum / pathology. Urinary Bladder Diseases / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Cystectomy. Cystoscopy. Diagnosis, Differential. Hematuria / etiology. Humans. Male. Tomography, X-Ray Computed. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792856.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


17. Miao XP, Li JS, Li HY, Zeng SP, Zhao Y, Zeng JZ: Expression of ornithine decarboxylase in precancerous and cancerous gastric lesions. World J Gastroenterol; 2007 May 28;13(20):2867-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We studied the expression of ODC in gastric mucosa from patients with chronic superficial gastritis (CSG, n=32), chronic atrophic gastritis [CAG, n=43; 15 with and 28 without intestinal metaplasia (IM)], gastric dysplasia (DYS, n=11) and gastric cancer (GC, n=48) tissues using immunohistochemical staining.
  • This finding indicates that ODC may be used as a good biomarker in the screening and diagnosis of precancerous lesions.
  • [MeSH-major] Adenocarcinoma / enzymology. Ornithine Decarboxylase / metabolism. Precancerous Conditions / enzymology. Stomach Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Gastric Mucosa / enzymology. Gastric Mucosa / pathology. Gastritis / enzymology. Gastritis / pathology. Gastritis, Atrophic / enzymology. Gastritis, Atrophic / pathology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Metaplasia / enzymology. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569126.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.1.1.17 / Ornithine Decarboxylase
  • [Other-IDs] NLM/ PMC4395642
  •  go-up   go-down


18. Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, Wong J: CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol; 2005 Apr;205(5):615-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
  • Overexpression of CDX2 was significantly associated with CDH17 in gastric adenocarcinoma.
  • Furthermore, the expression of CDX2 and LI-cadherin proteins was strongly coupled in intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cadherins / metabolism. Homeodomain Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Metaplasia / metabolism. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. Precancerous Conditions / metabolism. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732140.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH17 protein, human; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


19. Fine SW, Chan TY, Epstein JI: Inverted papillomas of the prostatic urethra. Am J Surg Pathol; 2006 Aug;30(8):975-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The remaining cases showed foci of squamous metaplasia with moderate atypia (n = 4), rare true papillary fronds in a classic inverted papilloma background (n = 2), or both (n = 1).
  • Eleven cases with prostatic tissue revealed adenocarcinoma of the prostate [n = 6; Gleason score 6 (n = 3) or 7 (n = 3)], high-grade prostatic intraepithelial neoplasia (n = 1), benign prostatic hypertrophy (n = 3), or adenosis (n = 1).
  • No patients had a prior history of either inverted papilloma or urothelial carcinoma, whereas 2 patients were diagnosed with high-grade urothelial carcinoma of the bladder synchronous with their inverted papilloma diagnosis.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Humans. Incidental Findings. Male. Middle Aged. Neoplasms, Multiple Primary / pathology. Prognosis. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861968.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Wong T, Tian J, Nagar AB: Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med; 2010 May;123(5):462-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
  • OBJECTIVES: Using a retrospective study design, we aim to demonstrate the impact of a Barrett's surveillance program on the stage of esophageal adenocarcinoma and identify factors for progression of metaplasia to cancer.
  • We report a retrospective review of a prospectively followed Barrett's cohort in a surveillance program and compared their outcome with patients with a new diagnosis of esophageal adenocarcinoma, identified at the same center between 1999 and 2005.
  • During the surveillance period of 987 patient-years, 5 (0.5% patient-year) patients developed esophageal adenocarcinoma.
  • During the same period, 46 patients were diagnosed with new-onset esophageal adenocarcinoma outside of our surveillance program.
  • CONCLUSION: Patients with Barrett's esophagus undergoing endoscopic surveillance benefit from early-stage cancer diagnosis.
  • Progression to adenocarcinoma is low, but long-segment and high-grade dysplasias have an increased risk of cancer.
  • A significant number of patients with newly diagnosed esophageal adenocarcinoma do not complain of gastroesophageal reflux disease and are therefore not investigated for Barrett's esophagus nor entered into surveillance.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20399324.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gil J, Błaszak A, Wojtuń S, Wojtkowiak M: [Endoscopic methods of gastro-esophageal reflux disease (GERD) treatment and their complications]. Pol Merkur Lekarski; 2007 May;22(131):429-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic character of GERD is associated with intestinal metaplasia and adenocarcinoma of the esophagus in its distal part.
  • [MeSH-minor] Animals. Barrett Esophagus / pathology. Barrett Esophagus / surgery. Esophagogastric Junction / pathology. Esophagogastric Junction / surgery. Fundoplication / methods. Humans. Laser Coagulation. Laser Therapy. Metaplasia. Monitoring, Ambulatory. Postoperative Complications. Proton Pump Inhibitors. Proton Pumps / drug effects

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679388.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors; 0 / Proton Pumps
  • [Number-of-references] 25
  •  go-up   go-down


22. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR: Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery; 2007 Jan;141(1):41-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prothymosin-alpha and ERp57 were previously identified as markers for gastric metaplasia in a mouse model of Helicobacter-induced gastric metaplasia and neoplasia.
  • In this paper we assess whether the expression of these putative biomarkers in humans is correlated with gastric metaplasia and adenocarcinoma and clinical outcomes.
  • CONCLUSIONS: These results suggest that although prothymosin-alpha is overexpressed in gastric adenocarcinoma, it is not associated with alterations in survival.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Down-Regulation. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Metaplasia / metabolism. Molecular Chaperones / metabolism. Prognosis. Protein Array Analysis. Retrospective Studies. Stomach / metabolism. Stomach / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188166.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA95103; United States / NCI NIH HHS / CA / CA67108; United States / NCI NIH HHS / CA / K12 CA090625; United States / NCI NIH HHS / CA / P50 CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Molecular Chaperones; 0 / Protein Precursors; 0 / prothymosin alpha; 61512-21-8 / Thymosin; EC 5.3.4.1 / Protein Disulfide-Isomerases; EC 5.3.4.1. / PDIA3 protein, human
  •  go-up   go-down


23. di Pietro M, Peters CJ, Fitzgerald RC: Clinical puzzle: Barrett's oesophagus. Dis Model Mech; 2008 Jul-Aug;1(1):26-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of oesophageal adenocarcinoma has increased dramatically in the Western world over the past two decades.
  • Owing to its dismal 5-year prognosis in advanced stages, early diagnosis is required in order to improve survival rates.
  • Barrett's is defined as the substitution of the normal stratified squamous epithelium of the oesophagus with a columnar cell lining with intestinal-type differentiation; a phenomenon commonly referred to as intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers / analysis. Cell Transformation, Neoplastic. Disease Progression. Early Diagnosis. Genetic Predisposition to Disease. Humans. Models, Biological

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Dec;129(6):2125-6; author reply 2126 [16344087.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):735-42 [16556175.001]
  • [Cites] Gut. 2006 Aug;55(8):1078-83 [16469795.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):423-31 [17064856.001]
  • [Cites] Nature. 2006 Nov 23;444(7118):444-54 [17122850.001]
  • [Cites] Gut. 2006 Dec;55(12):1810-20 [17124160.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Histopathology. 2007 Jun;50(7):920-7 [17543082.001]
  • [Cites] Gut. 2007 Jul;56(7):906-17 [17185354.001]
  • [Cites] Genet Med. 2007 Jun;9(6):341-7 [17575500.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):645-58 [17687385.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2788-803 [17974918.001]
  • [Cites] Gut. 2008 Feb;57(2):167-72 [17965067.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):89-94 [10767821.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):333-8 [10930368.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Gut. 2001 Mar;48(3):304-9 [11171817.001]
  • [Cites] Endoscopy. 2001 May;33(5):391-400 [11396755.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):549-55 [11505399.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jul;22(1):1-6 [12103364.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):60-6 [12109857.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):422-7 [12402314.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):457-9 [8781742.001]
  • [Cites] Br J Clin Pract. 1996 Jul-Aug;50(5):245-8 [8794600.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):697-701 [9125634.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jan;34(1):46-52 [9542635.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):730-9 [15971196.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):889-907 [16338648.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • (PMID = 19048049.001).
  • [ISSN] 1754-8411
  • [Journal-full-title] Disease models & mechanisms
  • [ISO-abbreviation] Dis Model Mech
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105365007
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2561971
  •  go-up   go-down


24. Zhang T, Zhang F, Han Y, Gu Z, Zhou Y, Cheng Q, Zhu Y, Zhang C, Wang Y: A rat surgical model of esophageal metaplasia and adenocarcinoma-induced by mixed reflux of gastric acid and duodenal contents. Dig Dis Sci; 2007 Nov;52(11):3202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rat surgical model of esophageal metaplasia and adenocarcinoma-induced by mixed reflux of gastric acid and duodenal contents.
  • Herein we report a novel rat surgical model in which esophageal metaplasia and adenocarcinoma develop as complications of MR.
  • Severe inflammatory and proliferative changes, high prevalence of esophageal metaplasia (78%), and adenocarcinoma (50%) were observed in the lower part of the esophagus of rats 20 weeks after surgery.
  • The resulting esophageal lesions resembled those described in humans and supported a progression from intestinal metaplasia to dysplasia and, ultimately, esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenostomy / methods. Esophageal Neoplasms / surgery. Esophagostomy / methods. Esophagus / pathology. Gastroesophageal Reflux / complications. Jejunostomy / methods
  • [MeSH-minor] Animals. Disease Models, Animal. Disease Progression. Duodenum / secretion. Gastric Acid / secretion. Male. Metaplasia / etiology. Metaplasia / pathology. Metaplasia / surgery. Models, Anatomic. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):193-4 [9040189.001]
  • [Cites] Ann Surg. 1992 Jul;216(1):35-43 [1632700.001]
  • [Cites] Semin Surg Oncol. 1997 Jul-Aug;13(4):270-80 [9229415.001]
  • [Cites] Gut. 1992 Nov;33(11):1454-8 [1452066.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):331-7 [11232672.001]
  • [Cites] Am J Gastroenterol. 1997 Jan;92(1):37-41 [8995934.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):57-67 [15213619.001]
  • [Cites] Surg Oncol. 1996 Aug;5(4):149-64 [9067563.001]
  • [Cites] Am J Gastroenterol. 1995 Feb;90(2):270-6 [7847299.001]
  • [Cites] Dig Dis Sci. 2000 Dec;45(12):2463-9 [11258576.001]
  • [Cites] Cancer Lett. 1997 Aug 19;117(2):161-74 [9377544.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):799-803 [10086669.001]
  • [Cites] Surgery. 1992 May;111(5):503-10 [1598670.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):66-73 [10228767.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Apr;107(4):1059-65; discussion 1065-6 [8159027.001]
  • [Cites] Cancer Res. 1979 Sep;39(9):3644-6 [476689.001]
  • [Cites] Dig Dis Sci. 1981 Jan;26(1):65-72 [7460707.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):904-9 [11063147.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):269-74 [8760598.001]
  • [Cites] Carcinogenesis. 1998 Aug;19(8):1445-9 [9744541.001]
  • [Cites] Gastroenterology. 1994 Sep;107(3):747-54 [8076761.001]
  • [Cites] Dis Esophagus. 2000;13(1):39-43 [11005330.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):260-8 [9841983.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2265-70 [9395230.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):369-77 [9149898.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):86-91 [9934736.001]
  • [Cites] Gut. 1999 May;44(5):598-602 [10205192.001]
  • [Cites] Arch Surg. 1992 Aug;127(8):951-5 [1642537.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):753-65 [15094711.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Surgery. 1980 Mar;87(3):280-5 [6767288.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):358-70; discussion 370-1 [8813264.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1186-91 [10235190.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1192-9 [8898632.001]
  • [Cites] Surgery. 1995 Jun;117(6):699-704 [7778033.001]
  • (PMID = 17393326.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. O'Connell F, Cibas ES: Cytologic features of ciliated adenocarcinoma of the cervix: a case report. Acta Cytol; 2005 Mar-Apr;49(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of ciliated adenocarcinoma of the cervix: a case report.
  • Because cilia are characteristically lost when malignant tumors arise at these sites, the detection of cilia on light microscopy is frequently used to support a benign diagnosis.
  • CASE: A woman with a histologically confirmed ciliated adenocarcinoma of the cervix had prior liquid-based cervical cytology showing atypical, ciliated glandular cells that initially raised the diagnostic consideration of tubal metaplasia.
  • A concurrent biopsy, however, revealed focally ciliated adenocarcinoma of the cervix.
  • CONCLUSION: Awareness of the ciliated variant of adenocarcinoma of the cervix is important to avoid overreliance on ciliation as a definitive feature of benignity in cervical cytologic specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Epithelial Cells / pathology. Mullerian Ducts / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cilia / pathology. Diagnosis, Differential. Diethylstilbestrol / adverse effects. Female. Humans. Pregnancy. Prenatal Exposure Delayed Effects. Vaginal Smears


26. Schmassmann A, Gebbers JO: [Barrett's esophagus: diagnosis and therapy]. Praxis (Bern 1994); 2005 May 25;94(21):861-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett's esophagus: diagnosis and therapy].
  • Barrett's esophagus is usually diagnosed by the endoscopic and histological finding of columnar epithelium with intestinal metaplasia in the distal esophagus.
  • Barrett mucosa predisposes patients to adenocarcinoma that develops in approximately 0.5% of these patients per year (Barrett mucosa --> dysplasia --> cancer sequence).
  • The incidence of esophageal adenocarcinoma over the past few decades; the present incidence, however, is still rather low and is reported to be approximately 4 and approximately 0.5 per 100,000 in males and females, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cell Transformation, Neoplastic / pathology. Esophagitis, Peptic / complications. Esophagitis, Peptic / pathology. Esophagitis, Peptic / therapy. Esophagoscopy. Esophagus / pathology. Female. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Male. Metaplasia. Middle Aged. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966485.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


28. Norimura D, Isomoto H, Nakayama T, Hayashi T, Suematsu T, Nakashima Y, Inoue N, Matsushima K, Yamaguchi N, Ohnita K, Mizuta Y, Inoue K, Shikuwa S, Nakao K, Kohno S: Magnifying endoscopic observation with narrow band imaging for specialized intestinal metaplasia in barrett's esophagus with special reference to light blue crests. Dig Endosc; 2010 Apr;22(2):101-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnifying endoscopic observation with narrow band imaging for specialized intestinal metaplasia in barrett's esophagus with special reference to light blue crests.
  • AIM: Barrett's esophagus (BE) with specialized intestinal metaplasia (SIM) is at high risk of esophageal adenocarcinoma.
  • RESULTS: IM pit pattern with ME-NBI for the diagnosis of IM yielded acceptable sensitivity, specificity and accuracy at 92%, 77% and 83%, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Endoscopy, Gastrointestinal / methods. Intestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Metaplasia. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447202.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Grassi A, Giannarelli D, Iacopini F, Paoluzi P, Iannetti A, Giovannelli L, Efrati C, Barberani F, Giovannone M, Tosoni M: Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett's esophagus. J Exp Clin Cancer Res; 2006 Sep;25(3):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett's esophagus.
  • The clinical importance of Barrett's esophagus is related to its correlation to adenocarcinoma.
  • The diagnosis is based on histologic demonstration of specialized intestinal metaplasia in the distal esophagus.
  • The aim of this study was to assess the prevalence of intestinal metaplasia of the distal esophagus in a population submitted to gastroscopy not selected for reflux disease, and with columnar lined distal esophagus between 0.5 and 2 cm.
  • In four Centers 224 patients received endoscopy with biopsies demonstrating specialized intestinal metaplasia in 21% of cases.
  • A significant association was present in over 70 (females), as well as with the presence of antral intestinal metaplasia demonstrated in 45 patients by gastric biopsies.
  • Biopsy samplings can diagnose the presence of intestinal metaplasia during endoscopy in patients endoscopically suspected for Barrett's esophagus: at present there is not clear evidence to promote this screening to achieve mortality reduction of esophageal adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / diagnosis. Endoscopy, Gastrointestinal. Esophagus / pathology. Intestinal Mucosa / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Metaplasia / epidemiology. Middle Aged. Prevalence

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167967.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


30. Filipec Kanizaj T, Katicić M, Presecki V, Gasparov S, Colić Cvrlje V, Kolarić B, Mrzljak A: Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. Croat Med J; 2009 Apr;50(2):124-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper gastrointestinal endoscopy was performed, endoscopic diagnosis recorded, and 4 mucosal biopsy samples were obtained and assessed according to Updated Sydney protocol.
  • Thirty patients had gastric adenocarcinoma, 126 peptic ulcers, and 51 normal finding. p120 (CagA) seropositivity was significantly more often present in patients with higher activity grade in the antrum (P = 0.025), p30 in patients with greater inflammation in the antrum (P = 0.025) and the corpus (P = 0.010), p33 in patients with greater inflammation in the corpus (P = 0.050), and p19 (OMP) in patients with lower intestinal metaplasia grades in the corpus (P = 0.025).

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] J Clin Pathol. 1994 Mar;47(3):227-31 [8163693.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Clin Microbiol. 1995 Jun;33(6):1496-500 [7650174.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 Jun;7(6):533-6 [7552635.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):310-7 [7496968.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):760-70 [8558837.001]
  • [Cites] Infect Immun. 1996 Apr;64(4):1166-72 [8606074.001]
  • [Cites] J Infect Dis. 1996 May;173(5):1171-5 [8627069.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):1-5 [8690507.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2829-33 [8698518.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1161-81 [8827022.001]
  • [Cites] J Clin Pathol. 1996 Oct;49(10):829-32 [8943750.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):759-62 [9259572.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):375-9 [9517643.001]
  • [Cites] J Clin Microbiol. 1998 Apr;36(4):931-6 [9542911.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):55-61 [9577374.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1517-21 [10364017.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2306-11 [10364602.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2348-9 [10364612.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):2113-4 [10383258.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Jul;6(4):489-93 [10391848.001]
  • [Cites] Int J Med Microbiol. 2006 Aug;296(4-5):223-8 [16600680.001]
  • [Cites] APMIS. 2008 Jun;116(6):465-76 [18754320.001]
  • [Cites] Scand J Gastroenterol. 1999 Oct;34(10):981-6 [10563667.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1308-15 [10579972.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):274-9 [10640957.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1530-5 [10738209.001]
  • [Cites] FEMS Immunol Med Microbiol. 2000 Jun;28(2):139-41 [10799804.001]
  • [Cites] Helicobacter. 2000;5 Suppl 1:S3-9; discussion S27-31 [10828748.001]
  • [Cites] Croat Med J. 2000 Jun;41(2):159-62 [10853044.001]
  • [Cites] Res Microbiol. 2000 Apr;151(3):191-200 [10865946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):981-5 [11008919.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):647-54 [11159201.001]
  • [Cites] Scand J Gastroenterol. 2001 Apr;36(4):351-5 [11336157.001]
  • [Cites] Lijec Vjesn. 2002 Sep;124 Suppl 1:5-9 [12592807.001]
  • [Cites] Scand J Gastroenterol. 2004 Mar;39(3):222-6 [15074390.001]
  • [Cites] Croat Med J. 2004 Oct;45(5):592-8 [15495287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Infect Immun. 1994 May;62(5):1557-65 [8168917.001]
  • (PMID = 19399945.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Other-IDs] NLM/ PMC2681059
  •  go-up   go-down


31. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L: Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology; 2005 Dec;129(6):1825-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Barrett's esophagus (BE) is associated with esophageal adenocarcinoma, the incidence of which has been increasing dramatically.
  • The prevalence of BE in the general population is uncertain because upper endoscopy is required for diagnosis.
  • BE was diagnosed when specialized intestinal metaplasia was detected histologically in suspected CLE.
  • [MeSH-major] Barrett Esophagus / diagnosis. Barrett Esophagus / epidemiology. Esophagus / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / physiopathology. Adult. Aged. Aged, 80 and over. Alcohol Drinking. Biopsy. Endoscopy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / physiopathology. Female. Gastroesophageal Reflux / diagnosis. Gastroesophageal Reflux / pathology. Humans. Male. Middle Aged. Risk Factors. Smoking. Surveys and Questionnaires. Sweden / epidemiology


32. Bresalier R: Barrett's Metaplasia: defining the problem. Semin Oncol; 2005 Dec;32(6 Suppl 8):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's Metaplasia: defining the problem.
  • Concern over how best to manage individuals with Barrett's esophagus (BE) has grown because of the consistent rise in the incidence of esophageal adenocarcinoma.
  • Since the 1970s, the rate of increase in incidence of esophageal adenocarcinoma has been greater than that for any other cancer in the US population.
  • Much remains to be learned about BE and its association with adenocarcinoma before effective surveillance or management strategies can be defined and implemented.
  • In this article, the relationship between BE and gastroesophageal reflux disease, risk for adenocarcinoma, and prospects for molecular diagnosis are discussed.
  • [MeSH-minor] Humans. Metaplasia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360008.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


33. Murphy JO, Ravi N, Byrne PJ, McDonald GS, Reynolds JV: Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. J Surg Res; 2008 Mar;145(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reflux-induced injury and oxidative stress result in esophageal inflammation and the potential for progression to intestinal metaplasia and adenocarcinoma.
  • No animal developed metaplasia or tumor.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727884.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cyclooxygenase 2 Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


34. González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, Sala N, Capella G, Sanz-Anquela JM: Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer; 2010 Dec 1;127(11):2654-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study included 478 patients who underwent gastric biopsy in 1988-1994 with diagnoses of normal mucosa, nonatrophic gastritis (NAG), non-metaplastic multifocal atrophic gastritis (MAG) and complete or incomplete intestinal metaplasia (IM) and who accepted to undergo a new biopsy during 2005-2007 or had an event during follow up.
  • Inter- and intra-observer variability of histological diagnosis was assessed.
  • Out the 21 adenocarcinomas, 16 had an incomplete IM in the baseline diagnosis.
  • Incomplete IM (HR 11.3; 95% CI 3.8-33.9) and a family history of GC (HR 6.1; 95% CI 1.7-22.4) were the strongest risk factors for gastric adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Retrospective Studies. Risk Factors. Spain / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178099.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Sargan I, Motoc A, Vaida MA, Bolintineanu S, Vîscu S: Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol; 2006;47(2):163-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts in perfecting the methods of early diagnosis, in trying to assess premalignant conditions, and in properly staging malignant tumors are still in trend.
  • Most gastric carcinomas are adenocarcinoma, 404 (90%) cases--could be classified as follows: 167 cases of tubular adenocarcinoma; 39 cases of papillary adenocarcinoma; 24 cases of mucinous or colloid adenocarcinoma; 141 "signet ring"-cell carcinoma; 33 cases of undifferentiated carcinoma.
  • Attention should be given to precancerous conditions; there was a large number of premalignant or potentially malignant gastric damage: atrophic chronic gastritis (54 cases), intestinal metaplasia (104 cases), and gastric dysplasia (104 cases).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy. Female. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106525.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


36. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K: Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol; 2007 Jan;14(1):166-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metaplastic breast cancer (MBC) is characterized by various combinations of adenocarcinoma, mesenchymal, and other epithelial components.
  • It was officially recognized as a distinct pathologic diagnosis in 2000.
  • METHODS: Data from patients with MBC and IDC reported to the National Cancer Database from January 2001 through December 2003 were reviewed for year of diagnosis, patient age, race/ethnicity, tumor size, nodal status, American Joint Committee on Cancer (AJCC) stage, tumor grade, hormone receptor status, and initial treatment, and were analyzed statistically by the Pearson chi(2) test.
  • [MeSH-minor] Databases, Factual. Humans. Metaplasia. United States

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066230.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ormeci N, Savas B, Coban S, Palabiyikoğlu M, Ensari A, Kuzu I, Kursun N: The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma. Surg Endosc; 2008 Mar;22(3):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma.
  • BACKGROUND: Barrett's esophagus is a condition that is premalignant for adenocarcinoma of the esophagus and the esophagogastric junction.
  • Early detection of Barrett's metaplasia and dysplasia is very important to decrease the mortality and morbidity from esophageal adenocarcinoma cancer.
  • This study aimed to evaluate the effectiveness of methylene blue-targeted biopsies in the differential diagnosis of intestinal metaplasia, dysplasia, and superficial esophageal carcinoma.
  • However, there was no statistical difference between the two methods in the diagnosis of esophagitis or esophageal carcinoma (p > 0.05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Risk Assessment. Sensitivity and Specificity. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1998 Jul;48(1):26-31 [9684660.001]
  • [Cites] Endoscopy. 2004 Jul;36(7):590-4 [15243880.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Endoscopy. 2005 Jan;37(1):8-18 [15657852.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Dig Dis Sci. 2002 Sep;47(9):2108-11 [12353864.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):403-9 [11522995.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):559-65 [11323579.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):461-79, ix [12134613.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 May;46(2):187-206 [12711361.001]
  • [Cites] Endoscopy. 2005 Jun;37(6):583-6 [15933935.001]
  • [Cites] Endoscopy. 2005 Sep;37(9):879-920 [16116544.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):670-7 [10734018.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Scand J Gastroenterol. 1993 Mar;28(3):193-6 [8446842.001]
  • [Cites] Endoscopy. 2001 Nov;33(11):909-16 [11668398.001]
  • [Cites] Endoscopy. 2001 May;33(5):391-400 [11396755.001]
  • [Cites] Dig Dis Sci. 2000 Feb;45(2):225-9 [10711429.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Dig Dis Sci. 2005 Feb;50(2):389-93 [15745106.001]
  • [Cites] Gut. 2001 Mar;48(3):314-9 [11171819.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):560-8 [10805842.001]
  • [Cites] Lancet. 2003 Aug 2;362(9381):373-4 [12907012.001]
  • [Cites] Endoscopy. 2004 Feb;36(2):103-9 [14765307.001]
  • [Cites] Am J Med. 2001 Dec 3;111 Suppl 8A:130S-136S [11749938.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):1-7 [8836709.001]
  • [Cites] Endoscopy. 1999 May;31(4):325-8 [10376462.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):47-52 [11154488.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):441-60 [12134612.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Gastrointest Endosc. 2001 Mar;53(3):333-5 [11231393.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Endoscopy. 2002 Aug;34(8):604-10 [12173079.001]
  • [Cites] Gut. 2003 Jan;52(1):18-23 [12477753.001]
  • (PMID = 17704887.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] T42P99266K / Methylene Blue
  •  go-up   go-down


38. McGowan CE, Lagares-Garcia JA, Bhattacharya B: Retained capsule endoscope leading to the identification of small bowel adenocarcinoma in a patient with undiagnosed Crohn disease. Ann Diagn Pathol; 2009 Dec;13(6):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retained capsule endoscope leading to the identification of small bowel adenocarcinoma in a patient with undiagnosed Crohn disease.
  • Subsequent laparoscopy led to the identification of severe, active Crohn disease with strictures, ulcers, crypt abscesses, pyloric metaplasia, and transmural inflammation.
  • Extensive flat and polypoid high- and low-grade dysplasia were present, as well as an area of well-differentiated adenocarcinoma invading into the muscularis propria.
  • We discuss the epidemiology, pathogenesis, and diagnosis of small bowel malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Capsule Endoscopy. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Aged. Humans. Male. Neoplasm Staging. Staining and Labeling. Treatment Outcome


39. Bisceglia M, D'Angelo VA, Guglielmi G, Dor DB, Pasquinelli G: Dedifferentiated chordoma of the thoracic spine with rhabdomyosarcomatous differentiation. Report of a case and review of the literature. Ann Diagn Pathol; 2007 Aug;11(4):262-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was referred to our neurosurgical unit with a history of an irradiated metastatic adenocarcinoma to the thoracic vertebra, a diagnosis that was rendered 3 years earlier at another hospital on presentation.
  • A final diagnosis of dedifferentiated chordoma with rhabdomyoblastic differentiation was finally established.
  • Rhabdomyoblastic metaplasia is a novelty in dedifferentiated chordoma.

  • Genetic Alliance. consumer health - Chordoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630110.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Raspollini MR, Taddei GL, Marchionni M, Bacci S, Romagnoli P: Differential diagnosis between uterine carcinosarcoma versus carcinoma with sarcomatous metaplasia: an immunohistochemical and ultrastructural case study. Ultrastruct Pathol; 2005 Mar-Apr;29(2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis between uterine carcinosarcoma versus carcinoma with sarcomatous metaplasia: an immunohistochemical and ultrastructural case study.
  • Electron microscopy showed the neoplastic tissue to be made of a single population of poorly differentiated epithelial cells, thus confirming the immunohistochemical findings and leading to the diagnosis of uterine metaplastic carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinosarcoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Metaplasia / diagnosis. Sarcoma / diagnosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028671.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Herszényi L, Pregun I, Tulassay Z: Diagnosis and recognition of early esophageal neoplasia. Dig Dis; 2009;27(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and recognition of early esophageal neoplasia.
  • Barrett's esophagus (BE) is the precursor lesion of esophageal adenocarcinoma, a malignancy with increasing incidence in Western countries.
  • Malignant transformation of Barrett's metaplasia is a multistep process in which intestinal metaplasia progresses through low-grade and high-grade dysplasia into eventually invasive cancer.
  • The exact incidence of progression from BE to esophageal adenocarcinoma is unknown.
  • Endoscopic surveillance and follow-up are advised in order to detect adenocarcinoma and its precursor precancerous lesions at an early and curable stage, although there has been much debate on this topic.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / complications. Esophageal Neoplasms / diagnosis. Esophagoscopy. Precancerous Conditions / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439957.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media
  • [Number-of-references] 60
  •  go-up   go-down


42. Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon DK, Johnson TD, Appelman H, Beer DG, Wang TD: Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology; 2010 Nov;139(5):1472-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Peptide selection was performed using phage display by removing nonspecific binders using Q-hTERT (intestinal metaplasia) cells and achieving specific binding against OE33 (esophageal adenocarcinoma) cells.
  • On esophageal specimens (n = 12), the fluorescence intensity (mean ± SEM) in 1-mm intervals classified histologically as squamous (n = 145), intestinal metaplasia (n = 83), dysplasia (n = 61), and gastric mucosa (n = 69) was 46.5 ± 1.6, 62.3 ± 5.8, 100.0 ± 9.0, and 42.4 ± 3.0 arb units, respectively.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Am J Med. 2002 Oct 15;113(6):499-505 [12427500.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):406-14 [11832455.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] Gut. 2004 Aug;53(8):1070-4 [15247170.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Int J Pept Protein Res. 1990 Mar;35(3):161-214 [2191922.001]
  • [Cites] Science. 1990 Jul 27;249(4967):386-90 [1696028.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82 [2201029.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5907-16 [15994969.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):867-72 [16981102.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6049-55 [17947467.001]
  • [Cites] Nat Med. 2008 Apr;14(4):454-8 [18345013.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):24-31 [18442484.001]
  • [Cites] Arch Pathol Lab Med. 2008 Oct;132(10):1577-85 [18834215.001]
  • [Cites] Leukemia. 2009 Feb;23(2):235-44 [19151784.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):105-19 [18975117.001]
  • [Cites] Lancet. 2009 Mar 7;373(9666):850-61 [19269522.001]
  • [Cites] Mol Biosyst. 2009 Nov;5(11):1279-91 [19823742.001]
  • [Cites] Am J Clin Pathol. 2009 Jul;132(1):94-100 [19864239.001]
  • [Cites] N Engl J Med. 2009 Dec 24;361(26):2548-56 [20032324.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):435-46 [19852961.001]
  • [Cites] J Natl Cancer Inst. 2010 Feb 24;102(4):271-4 [20075370.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):828-33.e1 [20096697.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1183-90 [12807723.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1341-7 [10728696.001]
  • [Cites] Cell Growth Differ. 2001 Apr;12(4):201-10 [11331249.001]
  • [CommentIn] Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):3 [21265056.001]
  • (PMID = 20637198.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U54 CA163059; United States / NCI NIH HHS / CA / U54 CA163059-01; United States / NCI NIH HHS / CA / U54 CA13642; United States / NCI NIH HHS / CA / U54 CA136429; United States / NCI NIH HHS / CA / U54 CA136429-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / Carrier Proteins
  • [Other-IDs] NLM/ NIHMS365874; NLM/ PMC3319360
  •  go-up   go-down


43. Lamarque D, Levy M, Chaumette MT, Roudot-Thoraval F, Cavicchi M, Auroux J, Courillon-Mallet A, Haioun C, Delchier JC: Frequent and rapid progression of atrophy and intestinal metaplasia in gastric mucosa of patients with MALT lymphoma. Am J Gastroenterol; 2006 Aug;101(8):1886-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent and rapid progression of atrophy and intestinal metaplasia in gastric mucosa of patients with MALT lymphoma.
  • OBJECTIVES: Association of gastric mucosa-associated lymphoid tissue (MALT) low-grade lymphoma and adenocarcinoma has repeatedly been reported.
  • The aim of this study was to evaluate the frequency and the spreading of atrophy and intestinal metaplasia in gastric mucosa of patients with gastric MALT lymphoma followed after conservative treatment.
  • Univariate and multivariate analysis evaluated the association between the appearance of atrophy and intestinal metaplasia in antrum or corpus and different factors related to patients, H. pylori status, lymphoma features, and treatment.
  • In addition, histological aspects of gastric biopsies at the diagnosis period and at the end of follow-up were compared with those of two control groups of age-matched patients with H. pylori gastritis.
  • RESULTS: At the diagnosis time, only intestinal metaplasia in corpus was more frequent in patients with gastric MALT lymphoma than in patients with nonulcer dyspepsia.
  • Within median follow-up of 54.4 months (range 9-196), the percentage of patients with gastric atrophy and intestinal metaplasia increased significantly and became significantly higher than in age-matched nonulcer dyspepsia patients.
  • Multivariate analysis showed significant association between corpus intestinal metaplasia and corpus atrophy, intestinal metaplasia in antrum, and duration of the follow-up.
  • CONCLUSIONS: Conservative management of gastric MALT lymphoma including H. pylori eradication is associated with progression of gastric atrophy and intestinal metaplasia with frequent involvement of the corpus which is known to be a precancerous condition.
  • [MeSH-minor] Atrophy. Chi-Square Distribution. Disease Progression. Female. Gastroscopy. Helicobacter Infections / drug therapy. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Metaplasia. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780555.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Fujita M, Fujimori T, Chiba T: [The definition of Barrett's esophagus]. Nihon Rinsho; 2005 Aug;63(8):1325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They proposed that BE was a chance in the esophageal epithelium of any length that can be recognized at endoscopy, and confirmed to have intestinal metaplasia by biopsy of the tubular esophagus and excludes intestinal metaplasia of the cardia.
  • Especially SCE is distinctive features of BE, available for diagnosis.
  • On the other hand, BE is premalignant condition for the adenocarcinoma of the esophagus, therefore the features of the BE are researched to prevent and find out earlier development of adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Esophagoscopy. Gastroesophageal Reflux / complications. Humans

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101217.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


45. Chaves P, Cruz C, Dias Pereira A, Suspiro A, de Almeida JC, Leitão CN, Soares J: Gastric and intestinal differentiation in Barrett's metaplasia and associated adenocarcinoma. Dis Esophagus; 2005;18(6):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric and intestinal differentiation in Barrett's metaplasia and associated adenocarcinoma.
  • Intestinal metaplasia is a prerequisite criterion for the diagnosis of Barrett's metaplasia and the sole columnar esophageal lining associated with malignancy.
  • The cellular heterogeneity of Barrett's metaplasia is well documented but the relationship between the distinct cell subtypes and neoplasia is unclear.
  • We studied 46 columnar-lined esophageal segments, 15 with associated adenocarcinoma.
  • In metaplasia there were no differences in MUC5AC and MUC6 immunoreactivity, between cases with and without associated neoplasia, except for goblet elements producing MUC6 that were exclusive of metaplasia adjacent to adenocarcinoma (P < 0.05).
  • In metaplasia it was restricted to Barrett's cases and was more frequent in areas with intestinal metaplasia.
  • Columnar-lined esophagus without intestinal metaplasia did not express MUC2.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16336609.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastric Mucins; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / apomucin
  •  go-up   go-down


46. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T, Koichi M: A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis; 2005 Mar;26(3):565-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.
  • Barrett's esophagus (BE) and esophageal adenocarcinoma (ADC) is associated with reflux of duodenal contents.
  • [MeSH-major] Adenocarcinoma / prevention & control. Cyclooxygenase Inhibitors / pharmacology. Esophageal Neoplasms / prevention & control. Esophagitis / prevention & control. Metaplasia / prevention & control. Prostaglandin-Endoperoxide Synthases / drug effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15564290.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


47. Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA: Molecular mechanisms in Barrett's metaplasia and its progression. Semin Oncol; 2007 Apr;34(2 Suppl 1):S2-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms in Barrett's metaplasia and its progression.
  • The dramatic increase in the incidence and poor overall survival rates of esophageal/gastroesophageal junction adenocarcinoma underscore the necessity to discover molecular markers that can be used for risk assessment, early diagnosis, and targeted therapeutic intervention.
  • Barrett's esophagus (BE) is proposed to represent a precursor of esophageal/gastroesophageal junction adenocarcinoma.
  • BE progression to invasive cancer is defined by a metaplasia-dysplasia-carcinoma progression characterized by an increasing accumulation of genetic changes associated with alterations in molecular gatekeepers of cell circuitries and tissue homeostasis.
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Chemoprevention. Cyclin D1 / physiology. Disease Progression. Early Diagnosis. Humans. Metaplasia. NF-kappa B / physiology. Risk Assessment. Signal Transduction / physiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449347.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 86390; United States / NIDCR NIH HHS / DE / R01 DE 13157-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 136601-57-5 / Cyclin D1
  •  go-up   go-down


48. Bansal A, Kahrilas PJ: Treatment of GERD complications (Barrett's, peptic stricture) and extra-oesophageal syndromes. Best Pract Res Clin Gastroenterol; 2010 Dec;24(6):961-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from typical reflux symptoms and oesophagitis, the clinical presentation of GERD can be dominated by mucosal complications of reflux (Barrett's oesophagus, oesophageal adenocarcinoma, Peptic structure) or by extra-oesophageal syndromes, most notably asthma, laryngitis, or chronic cough.
  • With respect to adenocarcinoma, metaplasia and dysplasia are recognised precursors, but the potential of these lesions to evolve to cancer has not been shown to lessen as a result of treatment, medical or surgical.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • [Cites] Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:54-9 [14725580.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2390-4 [14638338.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):633-7 [15026893.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):1877-83 [15447744.001]
  • [Cites] Gastroenterology. 2004 Oct;127(4):1233-8 [15481000.001]
  • [Cites] J Clin Gastroenterol. 1984 Apr;6(2):109-12 [6715848.001]
  • [Cites] Chest. 1987 Oct;92(4):757-8 [3652768.001]
  • [Cites] Gastrointest Endosc. 1995 Mar;41(3):189-95 [7789675.001]
  • [Cites] Am J Gastroenterol. 1999 Mar;94(3):632-6 [10086643.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):13-7 [10385715.001]
  • [Cites] Gut. 1999 Oct;45(4):489-94 [10486353.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Am J Gastroenterol. 2005 Nov;100(11):2419-25 [16279894.001]
  • [Cites] BMJ. 2006 Jan 7;332(7532):11-7 [16330475.001]
  • [Cites] Laryngoscope. 2006 Feb;116(2):254-60 [16467715.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):433-41 [16616347.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1091-7 [16357331.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2685-92 [17227515.001]
  • [Cites] Dig Dis Sci. 2007 Feb;52(2):463-8 [17211695.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1226-33 [17408660.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Mar;265(3):357-64 [17899143.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Sep;139(3):414-20 [18722223.001]
  • [Cites] Am J Gastroenterol. 2008 Dec;103(12):2988-94 [18786110.001]
  • [Cites] Am J Gastroenterol. 2009 Feb;104(2):502-13 [19174812.001]
  • [Cites] N Engl J Med. 2009 Apr 9;360(15):1487-99 [19357404.001]
  • [Cites] N Engl J Med. 2009 May 28;360(22):2277-88 [19474425.001]
  • [Cites] Am J Gastroenterol. 2009 Jun;104(6):1366-73 [19491850.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):440-4 [19410576.001]
  • [Cites] Am J Gastroenterol. 2009 Nov;104(11):2684-92 [19690526.001]
  • [Cites] Clin Gastroenterol Hepatol. 2010 Mar;8(3):235-44; quiz e32 [19850156.001]
  • [Cites] Gastroenterology. 2010 Apr;138(4):1297-301 [20080091.001]
  • [Cites] Gastrointest Endosc. 2010 Apr;71(4):680-5 [20363409.001]
  • [Cites] Dig Dis Sci. 2010 Jul;55(7):1918-31 [20405211.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1523-30 [20461069.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Jun;31(12):1268-75 [20236257.001]
  • [Cites] Gastroenterology. 2010 Sep;139(3):754-62 [20600028.001]
  • [Cites] Gastrointest Endosc. 2010 Sep;72(3):490-496.e1 [20598302.001]
  • [Cites] Thorax. 2001 Mar;56(3):198-204 [11182012.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):979-83 [11316215.001]
  • [Cites] Gastrointest Endosc. 2002 Dec;56(6):829-34 [12447293.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):987-99 [12809818.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1252-6 [12818265.001]
  • [Cites] Med J Aust. 2004 Apr 19;180(8):387-91 [15089728.001]
  • (PMID = 21126707.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK056033-09; United States / NIDDK NIH HHS / DK / R01 DK056033; United States / NIDDK NIH HHS / DK / R01 DK056033-09; United States / NIDDK NIH HHS / DK / R01 DK56033
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  • [Other-IDs] NLM/ NIHMS247533; NLM/ PMC3006235
  •  go-up   go-down


49. Wang XW, Gao HJ, Fang DC: Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma. J Dig Dis; 2008 May;9(2):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
  • Many studies have applied this technology for Barrett's metaplasia and adenocarcinoma, and identified a number of candidate genes useful as biomarkers in cancer staging, prediction of recurrence, prognosis and treatment selection.
  • This review described the gene expression profile and molecular changes related to Barrett's metaplasia and adenocarcinoma of the esophagus, with emphasis on its prognostic value and possibilities for targeted therapy in a clinical setting.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. Oligonucleotide Array Sequence Analysis / trends
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Metaplasia / diagnosis. Metaplasia / genetics. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419638.001).
  • [ISSN] 1751-2972
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 18
  •  go-up   go-down


50. Pantanowitz L, Otis CN: Cystitis glandularis. Diagn Cytopathol; 2008 Mar;36(3):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis ranges from benign conditions such as cystitis glandularis to adenocarcinoma.
  • Glandular cells of cystitis glandularis with intestinal metaplasia have a bland cytologic appearance.
  • If detected in a urine cytology specimen colonic metaplasia can be reported.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Choristoma / diagnosis. Cytodiagnosis. Diagnosis, Differential. Endometriosis / diagnosis. Female. Humans. Metaplasia. Urinalysis. Urinary Bladder Fistula / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232007.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M: Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol; 2006 Apr 28;12(16):2510-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
  • AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior.
  • METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed.
  • The latter resembled intestinal metaplasia with minimal nuclear atypia and irregular glands; two of these lesions demonstrated complete intestinal phenotype, while two demonstrated incomplete intestinal phenotype.
  • Because of its resemblance to normal gastric mucosa or mucosa with intestinal metaplasia, EWDA is often misdiagnosed.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Apr;91(4):839-48 [7513368.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1161-6 [8813081.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):867-70 [9625834.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1719-29 [10223565.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):104-6 [10393360.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):279-87 [10746668.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):713-8 [10854531.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):869-73 [12064010.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Br J Cancer. 1980 Feb;41(2):209-21 [6989383.001]
  • [Cites] Biochem J. 1980 Nov 1;191(2):645-8 [7016112.001]
  • [Cites] J Exp Med. 1981 Oct 1;154(4):1249-54 [6945392.001]
  • [Cites] Acta Pathol Jpn. 1983 Mar;33(2):395-401 [6869006.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):304-10 [1988372.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • (PMID = 16688795.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4087982
  •  go-up   go-down


52. Staats PN, Clement PB, Young RH: Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases. Am J Surg Pathol; 2007 Oct;31(10):1490-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary endometrioid adenocarcinoma of the vagina: a clinicopathologic study of 18 cases.
  • Vaginal adenocarcinoma is the second most common primary cancer of the vagina, yet there has been very little study of most subtypes other than clear cell carcinoma.
  • We reviewed 18 cases of primary vaginal endometrioid adenocarcinoma, in our experience the second most common subtype.
  • On microscopic examination, each of the tumors had a pure or predominant component of typical endometrioid adenocarcinoma.
  • There was squamous metaplasia in 4 cases, mucinous metaplasia in 4, and prominent nonvillous papillae in 2.
  • Other subtypes of adenocarcinoma (such as serous when the tumor has a papillary pattern) and atypical forms of endometriosis, including polypoid endometriosis, are the most common other differential diagnostic considerations.
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Cystadenocarcinoma, Serous / diagnosis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895749.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. van Dekken H, Hop WC, Tilanus HW, Haringsma J, van der Valk H, Wink JC, Vissers KJ: Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol; 2008 Nov;130(5):745-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When the successive stages along the metaplasia-low-grade dysplasia (LGD)-high-grade dysplasia (HGD)-adenocarcinoma axis were compared, protein overexpression of beta-catenin separated LGD from metaplasia, whereas protein overexpression of cyclin D1 and p53 discriminated HGD from LGD (all P <.001).
  • beta-Catenin can be helpful for a diagnosis of LGD in BE, although it stains positively in a subset only, whereas p53 remains an appropriate marker to define HGD.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cyclin D. Cyclins / biosynthesis. Disease Progression. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis. beta Catenin / biosynthesis


54. Hes O, Curík R, Mainer K, Michal M: Urothelial signet-ring cell carcinoma of the renal pelvis with collagenous spherulosis: a case report. Int J Surg Pathol; 2005 Oct;13(4):375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No signs of intestinal type of metaplasia and adenocarcinoma, changes similar to the cystitis cystica or cystitis glandularis, were found in the tumor or in its vicinity.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Collagen / analysis. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273199.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins; 9007-34-5 / Collagen
  •  go-up   go-down


55. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, South Australian Oesophageal Research Group: MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg; 2010 Jun;97(6):853-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.
  • BACKGROUND: The genetic changes that drive metaplastic progression from squamous oesophageal mucosa toward intestinal metaplasia and adenocarcinoma are unclear.
  • This study examined whether miRNAs play a role in the development of oesophageal adenocarcinoma.
  • METHODS: RNA was extracted from mucosa of normal oesophageal squamous epithelium, normal gastric epithelium, Barrett's oesophagus with intestinal metaplasia and oesophageal adenocarcinoma obtained from 16 individuals.
  • Expression of miR-143, miR-145 and miR-215 was lower in oesophageal adenocarcinoma than in Barrett's oesophagus.
  • MiR-205 levels were lower in gastric epithelium than in both Barrett's oesophagus and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Esophageal Neoplasms / genetics. MicroRNAs / analysis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20301167.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger
  • [Investigator] Wijnhoven BP; Hussey DJ; Watson DI; Smith CM; Mayne GC; Michael MZ; Astill D; Van der Hoek MB; Tsykin A; Tilanus HW; Wijnhoven BP
  •  go-up   go-down


56. Ringhofer C, Lenglinger J, Izay B, Kolarik K, Zacherl J, Eisler M, Wrba F, Chandrasoma PT, Cosentini EP, Prager G, Riegler M: Histopathology of the endoscopic esophagogastric junction in patients with gastroesophageal reflux disease. Wien Klin Wochenschr; 2008;120(11-12):350-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 19 patients with intestinal metaplasia (18.6%) were identified from 4-quadrant biopsies obtained at the squamocolumnar junction and at 0.5 cm distal from it.
  • Persons with intestinal metaplasia were significantly older, had increased frequency of endoscopic hiatal hernia, higher Hill grade and presence of endoscopic CLE (P < 0.05); no significant difference was observed regarding sex, endoscopic esophagitis or length of endoscopic and histopathologic CLE (P > 0.05).
  • The squamocolumnar junction harbors the highest yield of intestinal metaplasia.
  • [MeSH-major] Endoscopy, Digestive System. Esophagogastric Junction / pathology. Gastroesophageal Reflux / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / pathology. Biopsy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / pathology. Female. Gastric Mucosa / pathology. Hernia, Hiatal / diagnosis. Hernia, Hiatal / pathology. Humans. Male. Metaplasia. Middle Aged. Precancerous Conditions / diagnosis. Precancerous Conditions / pathology. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(13-14):405-11 [17671821.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1162-5 [17531009.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):11-21 [17592284.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1207-12 [12218577.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1611-6 [16863568.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1670-7 [14724819.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):150-3 [17591489.001]
  • [Cites] Gut. 1997 Nov;41(5):585-9 [9414961.001]
  • [Cites] Gut. 2003 Jun;52(6):791-6 [12740332.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):706-10 [17460453.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):164-9 [15679412.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):654-61 [16933002.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):212-7 [15046207.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1416-20 [16863541.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):522-30; discussion 530-2 [9351720.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Am J Gastroenterol. 2005 Aug;100(8):1853-67 [16144130.001]
  • [Cites] Gut. 1993 Jan;34(1):21-7 [8432446.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):470-1 [17609649.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):960-8 [12826888.001]
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):402-9 [10716154.001]
  • [Cites] Am J Gastroenterol. 2006 Jan;101(1):12-7 [16405528.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1065-70 [10582754.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1188-93 [11688579.001]
  • [Cites] Surg Endosc. 1999 Dec;13(12):1184-8 [10594262.001]
  • [Cites] Dis Esophagus. 1998 Apr;11(2):101-5 [9779365.001]
  • [Cites] Gut. 2003 Dec;52(12):1798; author reply 1798-9 [14633968.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):190-200 [15654800.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):235-8 [16391958.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Sep;24 Suppl 2:17-26 [16939429.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):929-36 [12826885.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2178-82 [17436103.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):302-11 [11866266.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S33-41 [15758657.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):920-4 [15309878.001]
  • [Cites] Gut. 1998 May;42(5):659-62 [9659160.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):893-902 [16165707.001]
  • [Cites] Dis Esophagus. 2003;16(1):24-8 [12581250.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(9-10):283-90 [17571232.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):619-26 [11685024.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):40-7 [16360414.001]
  • [Cites] Gut. 2004 Oct;53(10):1402-7 [15361485.001]
  • (PMID = 18709523.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


57. Sangoi AR, Berry G: Respiratory epithelial adenomatoid hamartoma: diagnostic pitfalls with emphasis on differential diagnosis. Adv Anat Pathol; 2007 Jan;14(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartoma: diagnostic pitfalls with emphasis on differential diagnosis.
  • The lesion can be confused with a variety of benign and malignant entities, including inflammatory polyp, inverted schneiderian papilloma, and low-grade sinonasal adenocarcinoma.
  • In reviewing the historical, clinical, gross, and histopathologic features of REAH and its subtypes, we elucidate how the distinction of REAH with florid mucinous metaplasia from low-grade adenocarcinoma can be challenging particularly in the setting of small biopsy samples.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenomatous Polyps / pathology. Biopsy. Diagnosis, Differential. Humans. Inflammation / pathology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198306.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


58. Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, Wang J, Canto M, Eshleman JR, Montgomery EA, Maitra A: Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine; 2008 Dec;4(4):295-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.
  • Esophageal adenocarcinoma arises in the backdrop of Barrett metaplasia-dysplasia sequence, with the vast majority of patients presenting with late-stage malignancy.
  • Mesothelin expression was assessed in esophageal tissue microarrays encompassing the entire histological spectrum of Barrett-associated dysplasia and adenocarcinoma.
  • Mesothelin was expressed in the esophageal adenocarcinoma cell line JH-EsoAd1 but not in primary human esophageal epithelial cells.
  • Anti-mesothelin antibody-conjugated nanoparticles can be useful for the diagnosis and therapy of mesothelin-overexpressing esophageal adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] J Phys Chem B. 2007 Jun 28;111(25):6969-72 [17552555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):495-506 [9309400.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):381-9 [15725808.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):390-9 [15725809.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):752-61 [15696124.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1497-504 [16224217.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):417-28 [16415794.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):24-30 [16540726.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20 [16702385.001]
  • [Cites] Cancer Detect Prev. 2006;30(2):180-7 [16647225.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):20-4 [17044192.001]
  • [Cites] Gene Ther. 2007 Aug;14(16):1189-98 [17581599.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):490-7 [17532030.001]
  • [Cites] Chest. 2007 Oct;132(4):1239-46 [17646232.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3214-24 [18451147.001]
  • [Cites] J Immunother. 2000 Jul-Aug;23(4):473-9 [10916757.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] N Engl J Med. 2002 Mar 14;346(11):836-42 [11893796.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):595-600 [12479219.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):238-43 [12966350.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):902-12 [13679454.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Methods Enzymol. 2003;373:507-28 [14714424.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):357-66 [15017593.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):11-6 [15261138.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Nano Lett. 2007 Mar;7(3):761-5 [17288490.001]
  • [Cites] Int J Cancer. 1994 Apr 1;57(1):90-7 [8150545.001]
  • (PMID = 18691948.001).
  • [ISSN] 1549-9642
  • [Journal-full-title] Nanomedicine : nanotechnology, biology, and medicine
  • [ISO-abbreviation] Nanomedicine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA119397-04; United States / NCI NIH HHS / CA / R01 CA119397; United States / NCI NIH HHS / CA / R01 CA119397-04; United States / NCI NIH HHS / CA / R01CA119397
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS79893; NLM/ PMC2606904
  •  go-up   go-down


59. Healy CF, Feeley L, Leen E, Walsh TN: Primary squamous cell carcinoma of the breast: value of positron emission tomography scanning in confirming the diagnosis. Clin Breast Cancer; 2006 Dec;7(5):413-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the breast: value of positron emission tomography scanning in confirming the diagnosis.
  • Controversy exists as to whether a pure form exists or whether described cases represent extreme squamous metaplasia within an adenocarcinoma.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239268.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Cook MB, Wild CP, Everett SM, Hardie LJ, Bani-Hani KE, Martin IG, Forman D: Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev; 2007 Oct;16(10):2090-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Circulatory disease mortality was borderline statistically significant (SMR, 1.24; 95% CI, 1.00-1.52; P = 0.053) for those with a specialized intestinal metaplasia diagnosis of BE.
  • It has also shown that those who have a histologic BE diagnosis may also have an increased risk of circulatory disease mortality.
  • [MeSH-major] Adenocarcinoma / mortality. Barrett Esophagus / mortality. Carcinoma, Squamous Cell / mortality. Esophageal Neoplasms / mortality. Neoplasms, Multiple Primary / mortality. Precancerous Conditions / mortality

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890521.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Clement PB: The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol; 2007 Jul;14(4):241-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the histologic diagnosis of endometriosis is usually straightforward, many diagnostic problems can arise as a result of alterations or absence of its glandular or stromal components.
  • The stromal component can be obscured or effaced by infiltrates of foamy and pigmented histiocytes, fibrosis, elastosis, smooth muscle metaplasia, myxoid change, and decidual change.
  • The histologic diagnosis of endometriosis can also be challenging when it involves an unusual or unexpected site.
  • Five such site-specific problematic areas considered are endometriosis on or near the ovarian surface, superficial cervical endometriosis, vaginal endometriosis, tubal endometriosis, and intestinal endometriosis, including the important distinction of an endometrioid carcinoma arising from colonic endometriosis from a primary colonic adenocarcinoma.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592255.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 139
  •  go-up   go-down


62. Barr H, Kendall C, Bazant-Hegemark F, Moayyedi P, Shetty G, Stone N: Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed; 2006;8(2):88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is now a clear causal relationship between symptomatic gastroesophageal reflux and esophageal adenocarcinoma (Lagergren et al, 1999).
  • The risk factor is now identified as Barrett's metaplasia (Solaymani et al, 2004).
  • There are profound challenges with the accurate endoscopic and pathologic detection and categorization of Barrett's metaplasia, dysplasia , and, indeed, cancer.
  • New endoscopic detection methods are being investigated to improve the diagnosis and definition of the premalignant phenotype.
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Disease Progression. Esophageal Neoplasms / etiology. Esophageal Neoplasms / pathology. Humans. Population Surveillance

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Apr 1;23(7):997-1005 [16573802.001]
  • [Cites] Dis Esophagus. 2000;13(1):5-11 [11005324.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Lancet. 2000 Dec 16;356(9247):2079-85 [11145505.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):7-12 [11208708.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gut. 2001 Dec;49(6):761-6 [11709508.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):588-90 [11845805.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Jan;16(1):41-50 [11856077.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):633-40 [11874995.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):820-3 [11875016.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):274-9 [11943125.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1319-27 [12094844.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):421-40, viii [12134611.001]
  • [Cites] Gut. 2002 Sep;51(3):313-4 [12171948.001]
  • [Cites] Gut. 2002 Sep;51(3):314-5 [12171949.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gut. 2002 Nov;51(5):620-1 [12377793.001]
  • [Cites] Gut. 2002 Nov;51(5):671-6 [12377805.001]
  • [Cites] Gut. 2003 Jan;52(1):18-23 [12477753.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Gut. 2003 Jan;52(1):28-33 [12477755.001]
  • [Cites] Ann Intern Med. 2003 Feb 4;138(3):176-86 [12558356.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1758-66 [12806608.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] J Pathol. 2003 Aug;200(5):602-9 [12898596.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):505-14 [14640762.001]
  • [Cites] Semin Gastrointest Dis. 2003 Jul;14(3):112-27 [14653411.001]
  • [Cites] J Gastroenterol. 2004 Jan;39(1):14-20 [14767729.001]
  • [Cites] Z Gastroenterol. 2004 Jun;42(6):499-504 [15190444.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):997-1003 [15286961.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):40-50 [8514061.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] Gut. 1995 Jul;37(1):7-12 [7672684.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):93-101 [8698231.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2291-3 [15571569.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2293-5 [15571570.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):561-74 [16185971.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):677-82 [10982761.001]
  • (PMID = 16926827.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  • [Other-IDs] NLM/ PMC1785170
  •  go-up   go-down


63. Park KJ, Soslow RA, Sonoda Y, Barakat RR, Abu-Rustum NR: Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. Gynecol Oncol; 2008 Sep;110(3):316-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.
  • OBJECTIVE: To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions.
  • METHODS: Histologic slides from 19 cases of radical trachelectomy performed for invasive endocervical adenocarcinoma were evaluated for correlation between the frozen and permanent sections of the endocervical margin.
  • An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al. was also applied to the frozen and permanent section slides and compared to the final diagnosis.
  • RESULTS: There was 84% concordance between the frozen-section and final diagnosis using histology alone, vs. 95% concordance using the Ioffe scoring system.
  • One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin, which in retrospect, was a benign lesion and was correctly classified using the Ioffe system.
  • Most of the discrepancies were due to misinterpretation of tubal metaplasia, tubo-endometrioid metaplasia, and atypical tubal metaplasia as adenocarcinoma in situ.
  • CONCLUSION: Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions, especially during frozen-section evaluation of the trachelectomy.
  • Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system, like that proposed by Ioffe et al., can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology


64. Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, Hölscher AH, Dienes HP, Baldus SE: Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis. World J Gastroenterol; 2005 Jun 7;11(21):3182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CDX2 represents a transcription factor for various intestinal genes (including MUC2) and thus an important regulator of intestinal differentiation, which could previously be identified in gastric carcinomas and intestinal metaplasia.
  • Both antigens were present in >80% of areas exhibiting intestinal metaplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / metabolism. Mucins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Early Diagnosis. Female. Humans. Male. Middle Aged. Mucin-2. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929165.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  • [Other-IDs] NLM/ PMC4316046
  •  go-up   go-down


65. Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S: A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma? Oncology (Williston Park); 2009 Feb;23(2):177-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma?
  • [MeSH-major] Adenocarcinoma / diagnosis. Cystitis / diagnosis. Kidney Neoplasms / diagnosis. Lymphatic Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Metaplasia. Nephrolithiasis / complications. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323300.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Musana AK, Resnick JM, Torbey CF, Mukesh BN, Greenlee RT: Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol; 2008 Mar;103(3):516-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Barrett's esophagus (BE) predisposes to adenocarcinoma of the esophagus and survival in esophageal adenocarcinoma is low.
  • Our objectives were to estimate the prevalence of diagnosed BE, estimate the annual incidence of initial diagnosis of BE, and characterize the demographics of patients diagnosed with BE.
  • All slides were retrieved and reviewed by a gastrointestinal pathologist to establish the presence of intestinal metaplasia and dysplasia.
  • Median age at diagnosis was 65.5 yr (range 17-94).
  • The incidence of an initial diagnosis of BE between 1996 and 2002 was 32.7 per 100,000 person-years (95% CI 27.1-38.2) and did not change significantly over the study period despite an increase in EGD rates.
  • At the initial diagnosis, 41.7% of the patients were on proton pump inhibitors.
  • CONCLUSION: The incidence of initial diagnosis of BE in a stable white population did not change significantly over a 7-yr period, despite an increase in EGD rates.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970839.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Amelink A, Haringsma J, Sterenborg HJ: Noninvasive measurement of oxygen saturation of the microvascular blood in Barrett's dysplasia by use of optical spectroscopy. Gastrointest Endosc; 2009 Jul;70(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Current investigations into endoscopic screening for the early detection of Barrett's esophageal adenocarcinoma have focused on visualization of the microvascular morphology by using narrow-band imaging (NBI).
  • RESULTS: The oxygen saturation of the microvascular blood remains high (approximately 90%) throughout the metaplasia-dysplasia-adenocarcinoma sequence.
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Fiber Optic Technology / methods. Gastroscopy / methods. Humans. Male. Middle Aged. Reproducibility of Results

  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 Jul;70(1):7-8 [19559830.001]
  • (PMID = 19249768.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA104677
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


68. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


69. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC: Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther; 2008 Feb 15;27(4):321-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been shown that the presence on diagnosis of endoscopic macroscopic markers indicates a high-risk group for Barrett's oesophagus.
  • AIM: To determine whether proton pump inhibitor therapy prior to diagnosis of Barrett's oesophagus influences markers for risk development of subsequent high-grade dysplasia/adenocarcinoma.
  • Five hundred and two patients diagnosed with Barrett's oesophagus were assessed on diagnosis for endoscopic macroscopic markers or low-grade dysplasia.
  • Subsequent development of high-grade dysplasia/adenocarcinoma was documented.
  • The relationship between the initiation of proton pump inhibitor therapy prior to the diagnosis of BE and the presence of macroscopic markers or low-grade dysplasia at entry was determined.
  • RESULTS: Fourteen patients developed high-grade dysplasia/adenocarcinoma during surveillance.
  • CONCLUSIONS: Use of proton pump inhibitor therapy prior to diagnosis of Barrett's oesophagus significantly reduced the presence of markers used to stratify patient risk.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Endoscopy, Gastrointestinal. Female. Humans. Incidence. Male. Metaplasia. Middle Aged. Population Surveillance. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047565.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors
  •  go-up   go-down


70. Arafa M, Boniver J, Delvenne P: Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):422-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For these reasons, a continuous effort is still needed to discover surrogate markers, which could support the final diagnosis.
  • Archival biopsies of normal ectocervical and endocervical tissues, squamous metaplasia, cervical intraepithelial neoplasia (CIN), squamous cell carcinoma, adenocarcinoma in situ, and adenocarcinoma were retrieved to perform a tissue microarray (TMA).
  • Involucrin positivity was better appreciated in well-differentiated diagnostic entities (ectocervix, mature metaplasia, and CIN I).


71. Sharma P: Narrow band imaging in Barrett's esophagus. Clin Gastroenterol Hepatol; 2005 Jul;3(7 Suppl 1):S21-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus is the premalignant lesion for esophageal and esophagogastric junction adenocarcinoma.
  • Currently, the diagnosis of metaplastic and dysplastic mucosa within the esophagus requires endoscopy with biopsy examination of abnormal-appearing tissue.
  • The presence of intestinal metaplasia and dysplasia within the esophagus often is patchy, and our current practices of performing standard endoscopy with random biopsy examinations are inaccurate.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012989.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


72. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Mean patient age at diagnosis was 72 years (range 58 to 93 y).
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Tantipalakorn C, Khunamornpong S, Lertprasertsuke N, Tongsong T: Female genital tract tumors and gastrointestinal lesions in the Peutz-Jeghers syndrome. J Med Assoc Thai; 2009 Dec;92(12):1686-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An ovarian microscopic cystadenoma was diagnosed together with a minimal deviation mucinous adenocarcinoma (MDA) of the uterine cervix and mucinous metaplasia in tubal mucosa and endometrium.
  • Pathological findings warranted a search for evidence of PJS Typical pigmentation at the hard palate and colonoscopic finding of hamartomatous polyps established the diagnosis of PJS.
  • The presented case suggests MDA and mucinous metaplasia warrant a search for PJS.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Tract / pathology. Genital Neoplasms, Female / pathology. Genitalia, Female / pathology. Peutz-Jeghers Syndrome / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Cystadenoma / pathology. Cystadenoma / surgery. Female. Humans. Hysterectomy. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Risk Factors. Salpingectomy

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043574.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


74. Singh R, Ragunath K, Jankowski J: Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut Liver; 2007 Dec;1(2):93-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies.
  • The incidence of Barrett's metaplasia and Barrett's adenocarcinoma has been increasing, but the prognosis of Barrett's adenocarcinoma is worse because individuals present at a late stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2007 Aug 1;26(3):501-7 [17635385.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):167-75 [16860063.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Mar;105(3):383-7; discussion 387-8 [8445916.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 2):S12-6 [10049441.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3383-7 [11151865.001]
  • [Cites] Am J Gastroenterol. 2007 Jan;102(1):21-3 [17266685.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Am J Gastroenterol. 2001 May;96(5):1355-62 [11374668.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):294-301 [11522968.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):641-7 [11979244.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):479-87 [12297761.001]
  • [Cites] Lasers Surg Med. 2003;32(1):10-6 [12516065.001]
  • [Cites] Endoscopy. 2003 Dec;35(12):998-1003 [14648410.001]
  • [Cites] J Biomed Opt. 2004 May-Jun;9(3):568-77 [15189095.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):671-8 [15855970.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1468-70 [15887128.001]
  • [Cites] Endoscopy. 2005 Oct;37(10):929-36 [16189764.001]
  • [Cites] Gut. 2006 Apr;55(4):442 [16531521.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):155-66 [16860062.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1392-9 [17101315.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):36-46 [17185078.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1154-61 [17433019.001]
  • [Cites] Gastroenterology. 1990 Oct;99(4):918-22 [2394347.001]
  • [Cites] Gastrointest Endosc. 1994 Nov-Dec;40(6):747-9 [7859976.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):1-7 [8836709.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):47-52 [11154488.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):289-93 [11522967.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):1888-95 [12190150.001]
  • [Cites] Gut. 2003 Jan;52(1):24-7 [12477754.001]
  • [Cites] Aliment Pharmacol Ther. 2003 May 15;17(10):1319-24 [12755845.001]
  • [Cites] Arch Pathol Lab Med. 2005 Feb;129(2):177-80 [15679415.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):679-85 [15855971.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Dec;19(6):889-907 [16338648.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Mar 15;23(6):735-42 [16556175.001]
  • [Cites] Gastrointest Endosc. 1989 Nov-Dec;35(6):541-4 [2480927.001]
  • (PMID = 20485625.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871632
  • [Keywords] NOTNLM ; Barrett's esophagus / Gastroesophageal reflux
  •  go-up   go-down


75. Chandrasoma P: Controversies of the cardiac mucosa and Barrett's oesophagus. Histopathology; 2005 Apr;46(4):361-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Confusion regarding the diagnosis of Barrett's oesophagus exists because of a false dogma that cardiac mucosa is normally present in the gastro-oesophageal junctional region.
  • When this fact is recognized, it becomes easy to develop precise histological definitions for the normal state (presence of only squamous and oxyntic mucosa), metaplastic oesophageal columnar epithelium (cardiac mucosa with and without intestinal metaplasia, and oxynto-cardiac mucosa), the gastro-oesophageal junction (the proximal limit of gastric oxyntic mucosa), the oesophagus (that part of the foregut lined by squamous and metaplastic columnar epithelium), reflux disease (the presence of metaplastic columnar epithelium), and Barrett's oesophagus (cardiac mucosa with intestinal metaplasia).
  • It is also possible to assess accurately the severity of reflux which is directly proportional to the amount of metaplastic columnar epithelium, and the risk of adenocarcinoma which is related to the amount of dysplasia in intestinal metaplastic epithelium present within the columnar lined segment of the oesophagus.
  • Histopathological precision cannot be matched by any other modality and can convert the confusion that exists regarding diagnosis of Barrett's oesophagus to complete lucidity in a manner that is simple, accurate, and reproducible.
  • [MeSH-minor] Esophagogastric Junction / pathology. Humans. Metaplasia

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Histopathology. 2006 Jul;49(1):97-8; author reply 98 [16842257.001]
  • (PMID = 15810947.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


76. Sosnovski V, Barenboim R, Cohen HI, Bornstein J: Complex Nabothian cysts: a diagnostic dilemma. Arch Gynecol Obstet; 2009 May;279(5):759-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: In rare cases in which the intracervical cysts assume very large dimensions, ultrasound and MRI can aid diagnosis, but may not always prevent the need for excision or hysterectomy.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cysts / diagnosis. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Colposcopy. Diagnosis, Differential. Female. Frozen Sections. Humans. Hysterectomy. Magnetic Resonance Imaging. Metaplasia


77. Chlumská A, Boudová L, Benes Z, Zámecník M: Histopathologic changes in gastroesophageal reflux disease. A study of 126 bioptic and autoptic cases. Cesk Patol; 2007 Oct;43(4):142-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic diagnosis of reflux esophagitis is still complicated by the lack of a consensus opinion on what is the normal mucosa in the area of the gastroesophageal junction (GEJ).
  • In 17 cases, CM displayed intestinal metaplasia (IM) predominantly of incomplete type and no dysplasia.
  • In one specimen of esophagus resected for adenocarcinoma, CM with incomplete IM was found in the vicinity of the tumor.


78. Bîrla R, Iosif C, Gîndea C, Hoară P, Constantinoiu S: [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):511-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical diagnosis of adenocarcinoma of the esophago-gastric junction].
  • The aim of the work paper is to present the diagnosis methods of the esophago-gastric junction adenocarcinoma, based on our experience and literature data.
  • The later reveal many novelties about diagnosis means in Barrett's esophagus (BE), the definition and classification of BE, as well as the progress of the endoscopical, immunohistochemical and molecular methods in surveillance of the dysplasia arising in BE and in detection of intraepithelial neoplasia.
  • Early esophago-gastric junction (EGJ) adenocarcinoma (AC) is asymptomatic and its detection may be possible only through endoscopical surveillance.
  • For this reason is necessary to use some more precise methods for identifying intestinal metaplasia on distal esophagus, in patients with gastro-esophageal reflux disease, as well as for risk stratification in patients with dysplasia and for detection of intraepithelial neoplasia.
  • Applying modern methods of immunohistochemical and molecular diagnosis on endoscopical biopsy or esophageal brushing samples, the diagnosis rate for BE, dysplasia and early AC is improved and using the imaging means permits to obtain preoperative TNM staging and tumoral type (Siewert), with implications in therapeutical management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Esophagogastric Junction. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / pathology. Diagnosis, Differential. Humans. Neoplasm Staging. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018349.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 47
  •  go-up   go-down


79. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • For the survival analysis, cases with distant metastasis upon diagnosis were excluded.
  • There was no association with intestinal metaplasia and/or H. pylori.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


80. Mihailovici MS, Danciu M, Ivan L, Ferariu D: Early gastric carcinoma diagnosed on endobiopsic and surgical specimens. Rom J Morphol Embryol; 2006;47(3):235-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: In this study, we reveal the importance of endobiopsy in EGC diagnosis.
  • The additional endobiopsies fragments presented chronic atrophic gastritis with H. pylori infection, intestinal metaplasia and dysplasia.
  • CONCLUSIONS: EGC had an incidence of 0.34%, which is very low because the lack of an endoscopical screening program favors the diagnosis of gastric cancer in advanced stages.
  • Both histological types--intestinal and diffuse, were present in EGC, associated with H. pylori chronic gastritis, intestinal metaplasia and dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308681.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


81. Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, Chaussade S, Kahan A: Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum; 2005 Sep;52(9):2882-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with SSc frequently develop gastroesophageal reflux, esophageal injury, and sometimes, intestinal metaplasia, or Barrett's esophagus (BE), which may increase the risk of esophageal adenocarcinoma.
  • This study sought to determine the prevalence of BE and esophageal adenocarcinoma in a cohort of SSc patients.
  • None of the patients with BE had adenocarcinoma, but 3 of the 14 patients (21%) had dysplasia on esophageal biopsy.
  • Although none of the patients had esophageal adenocarcinoma, patients with BE should be followed up closely, particularly patients with dysplasic BE.
  • Long-term prospective studies are warranted to determine the phenotype of SSc patients at high risk of developing dysplasia or esophageal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Cross-Sectional Studies. Enzyme Inhibitors / therapeutic use. Esophageal Neoplasms / complications. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / epidemiology. Female. France / epidemiology. Humans. Male. Middle Aged. Prevalence. Proton Pump Inhibitors


82. Segat D, Cassaro M, Dazzo E, Cavallini L, Romualdi C, Salvador R, Vitale MP, Vitiello L, Fassan M, Rugge M, Zaninotto G, Ancona E, Baroni MD: Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma. Histol Histopathol; 2010 05;25(5):551-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
  • Barrett's esophagus metaplasia is a pre-cancerous condition caused by chronic esophagitis.
  • Chromosomal instability (CIN) is common in Barrett's cells: therefore, we investigated the possible presence of centrosomal aberrations (a main cause of CIN) by centrosomal protein immunostaining in paraffined esophageal samples of patients who developed a Barrett's adenocarcinoma.
  • In most (55%) patients, alterations of the pericentriolar material (PCM) signals were evident and consistently marked the transition between normal epithelium to metaplasia.
  • Importantly, PCM altered signals in Barrett's mucosa and their apparent evolution in successive histopathological steps were correlated to adenocarcinoma aggressiveness, suggesting PCM as a possible prognostic marker for tumor relapse.
  • Extending our observations in a prospective study might help in the development of new prevention protocols for adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / metabolism. Centrosome / metabolism. Esophageal Neoplasms / metabolism. Esophagus / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens / metabolism. Chromosomal Instability. Female. Humans. Immunohistochemistry. Male. Metaplasia. Middle Aged. Models, Biological. Mucous Membrane / anatomy & histology. Mucous Membrane / metabolism. Mucous Membrane / pathology. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. Tubulin / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20238294.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens; 0 / Tubulin; 0 / pericentrin
  •  go-up   go-down


83. Peitz U, Malfertheiner P: [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention]. Z Gastroenterol; 2007 Dec;45(12):1264-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Barrett carcinoma--diagnosis, screening, surveillance, endoscopic treatment, prevention].
  • An adenocarcinoma of the distal esophagus may also be designated as Barrett's carcinoma as it evolves from Barrett's esophagus.
  • Barrett's esophagus currently is defined as a columnar metaplasia of the distal esophagus, as identified by endoscopy, that, upon histopathology, is confirmed to contain intestinal metaplasia.
  • A different histological entity of columnar metaplasia of the distal esophagus is cardia-type mucosa which probably precedes intestinal metaplasia, but lacks goblet cells typical for the latter.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Esophageal Neoplasms / diagnosis. Esophagoscopy. Mass Screening
  • [MeSH-minor] Early Diagnosis. Esophagus / pathology. Esophagus / surgery. Humans. Lymphatic Metastasis / pathology. Metaplasia. Neoplasm Invasiveness. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080229.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 127
  •  go-up   go-down


84. Nash JW, Bhardwaj A, Wen P, Frankel WL: Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study.
  • Maspin expression has been documented using immunohistochemical studies in pancreatic adenocarcinoma and high-grade intraductal dysplasia.
  • Immunohistochemistry was performed on tissue microarrays made from 72 cases of pancreatic ductal adenocarcinoma and 24 cases of chronic pancreatitis.
  • Diffuse and intense (3 +) staining was present in ducts with squamous metaplasia (3 cases).
  • Maspin may be helpful in differentiating ductal adenocarcinoma from chronic pancreatitis, once squamous metaplasia is ruled out.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536309.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


85. Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, Jankowski JA: Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):5936-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Met receptor signaling: a key effector in esophageal adenocarcinoma.
  • PURPOSE: The incidence of esophageal adenocarcinoma is rising, and survival rates remain poor.
  • We assessed the prognostic significance of Met expression in esophageal adenocarcinoma.
  • RESULTS: An increased expression of Met was seen along the metaplasia- adenocarcinoma sequence.
  • Inhibitors of Met may be effective treatment for esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / physiopathology. Esophageal Neoplasms / physiopathology. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062664.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA Primers; 0 / HGF protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


86. Zhang XL, Yang GZ, Ding HY: [Pathological study of radial sclerosing lesions]. Zhonghua Bing Li Xue Za Zhi; 2010 Jan;39(1):10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the pathological diagnostic features and the differential diagnosis of radial sclerosing lesions of the breast.
  • Dilated tubules and proliferated ducts or lobules were seen radically arranged at the periphery accompanied sometimes with the apocrine glands or columnar cell metaplasia and hyperplasia.
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Hyperplasia. Keratin-14 / metabolism. Keratins / metabolism. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388392.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-14; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


87. Weimann A, Zimmermann M, Gross M, Slevogt H, Rieger A, Morawietz L: CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma. Int J Surg Pathol; 2010 Oct;18(5):330-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
  • BACKGROUND: Barrett's mucosa is a risk factor for esophageal adenocarcinoma and should be detected at an early stage.
  • Aberrant CDX2 expression has been demonstrated in Barrett's metaplasia, esophagitis, and intestinal metaplasia of the stomach.
  • METHODS: The relationship between CDX2 and LI-cadherin expression was investigated in normal gastroesophageal (n = 24) and in Barrett's (n = 20) mucosa, in low-grade (n = 15) and high-grade (n = 13) intraepithelial neoplasia (IEN) as well as in esophageal adenocarcinoma (n = 16), using immunohistochemistry.
  • In adenocarcinoma, the expression of LI-cadherin and CDX2 was significantly weaker or absent.
  • CONCLUSIONS: CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract.
  • Both can be helpful for the early histologic diagnosis of Barrett's esophagus and its subsequent lesions; however, they do not significantly discern between different grades of dysplasia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Biomarkers / metabolism. Cadherins / metabolism. Homeodomain Proteins / metabolism

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444732.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDH17 protein, human; 0 / CDX2 protein, human; 0 / Cadherins; 0 / Homeodomain Proteins
  •  go-up   go-down


88. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, Kim WH: Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol; 2010 Dec;41(12):1664-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding focal adhesion kinase gene amplification, fluorescence in situ hybridization analysis showed focal adhesion kinase gene amplification in 34 (8.9%) of 384 gastric cancer specimens, whereas there was no amplification in any case of atrophy, intestinal metaplasia, or adenoma/dysplasia.
  • Thus, focal adhesion kinase gene amplification could supplement its protein expression for the diagnosis and treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Focal Adhesion Kinase 1 / genetics. Gene Amplification. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20869748.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


89. Chen X, Zhu LR, Hou XH: The characteristics of Barrett's esophagus: an analysis of 4120 cases in China. Dis Esophagus; 2009;22(4):348-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The island-type BE was predominant (56.80%), and the occurrence of BE with special intestinal metaplasia (SIM) was 36.58%, but SIM was more common in tongue-type BE than island-type and circumferential-type BE (both P < 0.001), as well as in long segment BE (LSBE) than in short segment BE (SSBE) (P < 0.001).
  • The incidence of adenocarcinoma was 0.61% patient-years of total follow up.
  • In China, the endoscopic prevalence of BE is lower, but the average age of diagnosis is younger; a high proportion of H. pylori infection is found in patients with BE, and about half of the patients have no typical symptoms of GERD; the tongue-type BE and the LSBE are apt to SIM.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Esophagus. 2009;22(5):475. Hou, Kiao-Hua [corrected to Hou, Xiao-hua]
  • (PMID = 19191861.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


90. Morgner-Miehlke A, Koop H, Blum AL, Hermans ML, Miehlke S, Labenz J: [Symptom- versus endoscopy-based diagnosis and treatment of gastroesophageal reflux disease (GERD)]. Z Gastroenterol; 2006 May;44(5):399-410
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Symptom- versus endoscopy-based diagnosis and treatment of gastroesophageal reflux disease (GERD)].
  • The preference for one or the other strategy depends on the prevalence of so-called alarm symptoms, risk factors for a reflux carcinoma or Barrett's metaplasia, demographic factors, e. g., age and gender, patient's wish and initial response to empirical therapy with proton pump inhibitors (PPI).
  • [MeSH-major] Endoscopy, Digestive System. Esophagitis, Peptic / diagnosis. Gastroesophageal Reflux / diagnosis. Practice Guidelines as Topic
  • [MeSH-minor] Adenocarcinoma / diagnosis. Anti-Ulcer Agents / therapeutic use. Barrett Esophagus / diagnosis. Diagnosis, Differential. Disease Progression. Esophageal Neoplasms / diagnosis. Humans. Long-Term Care. Proton Pump Inhibitors. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16688658.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors
  •  go-up   go-down


91. Yoshizawa N, Takenaka Y, Yamaguchi H, Tetsuya T, Tanaka H, Tatematsu M, Nomura S, Goldenring JR, Kaminishi M: Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest; 2007 Dec;87(12):1265-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori.
  • Spasmolytic polypeptide (TFF2)-expressing metaplasia (SPEM) is observed in mucosa adjacent to human gastric cancer and in fundic glands showing oxyntic atrophy in Helicobacter felis-infected mice.
  • Mongolian gerbils infected with Helicobacter pylori (Hp) develop goblet cell intestinal metaplasia and adenocarcinoma, but the presence of SPEM has not been studied in gerbils.
  • In uninfected animals, no SPEM or intestinal metaplasia was observed.
  • Goblet cell intestinal metaplasia developed only late in the infection.
  • Dual staining for TFF2 and MUC2 showed glands containing both SPEM- and MUC2-positive goblet cell intestinal metaplasia.
  • SPEM develops early in Hp infection in Mongolian gerbils, and alterations in gland morphology arise from SPEM glands during the course of gastric infection with goblet cell intestinal metaplasia developing subsequent to SPEM.
  • [MeSH-minor] Animals. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gerbillinae. Goblet Cells / metabolism. Goblet Cells / pathology. Male. Metaplasia


92. Fukasawa T, Suzuki S, Fujii H: [A case report of early gastric cancer with Paneth-like tumor cells]. Nihon Shokakibyo Gakkai Zasshi; 2006 Nov;103(11):1251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old man was given a diagnosis of grade 0IIc type gastric cancer of the midgastric posterior wall following endoscopy of the upper digestive tract, and subsequently underwent distal gastrectomy.
  • Tumor cells resembling Paneth cells were occasionally observed in differentiated adenocarcinoma that had invaded the submucosal layer, the tumor was CD10-positive, and showed differentiation to complete intestinal metaplasia.
  • Although complete intestinal metaplasia is associated with a low incidence of malignant transformation, this case was considered to be different from complete intestinal metaplasia, on which a mutation of the gene of p53 is involved in the early period of carcinogenesis.
  • [MeSH-major] Adenocarcinoma / pathology. Paneth Cells / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085906.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Bollito ER, Pacchioni D, Lopez-Beltran A, Volante M, Terrone C, Casetta G, Mari M, DePompa R, Cappia S, Papotti M: Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder. Anal Quant Cytol Histol; 2005 Aug;27(4):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Neuroendocrine (NE) cells are uncommon in primary adenocarcinoma (AC) and other glandular lesions of the bladder, with no recent study series concerning its significance in differential diagnosis, prognosis or biologic significance.
  • STUDY DESIGN: Sixteen primary bladder AC (enteric-type [n = 71, mucinous [n = 6] and not otherwise specified [NOS] [n = 31), 4 cases of urothelial carcinoma with glandular differentiation, 20 cases of glandular cystitis and 3 urachal remnants with intestinal metaplasia constituted the study series.
  • CONCLUSION: Primary bladder AC, cystitis glandularis and urachal remnants with intestinal metaplasia showed variable degrees of NE differentiation, with no apparent clinical correlation or prognostic significance.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220833.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


94. Sánchez-Fayos P, Martín Relloso MJ, González Guirado A, Porres Cubero JC: [Gastric adenocarcinoma: approach to a complex biological reality]. Med Clin (Barc); 2007 Jan 13;128(1):21-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma: approach to a complex biological reality].
  • [Transliterated title] Adenocarcinoma gástrico: intento de aproximación a una realidad biológica compleja.
  • The authors review the complex biological reality of gastric adenocarcinoma from several viewpoints.
  • A good knowledge of this complex biological reality will allow the identification of better markers for an early diagnosis as well as vulnerable etiopathogenetic points for a useful prevention and therapy.
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Achlorhydria / complications. Aged. Diet / adverse effects. Early Diagnosis. Epithelial Cells / cytology. Epithelial Cells / pathology. Female. Gastric Mucosa / pathology. Gastritis, Atrophic / complications. Helicobacter Infections / complications. Helicobacter pylori. Humans. Incidence. Male. Metaplasia. Middle Aged. Mitosis. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Risk Factors. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266889.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 107
  •  go-up   go-down


95. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • Normal esophageal, duodenal, colonic, biliary, and pancreatic duct mucosae, as well as gastric intestinal metaplasia, did not express Lgl2.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • However, the consistently negative anti-Lgl2 immunoreactivity seen in intestinal metaplasia does not allow differentiation of dysplasia from intestinal metaplasia with reactive change.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


96. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z: DEK overexpression in uterine cervical cancers. Pathol Int; 2008 Jun;58(6):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DEK protein expression was studied in 253 cervical lesions, including 30 non-neoplastic cervix with or without squamous metaplasia, 64 cervical intra-epithelial neoplasias (CIN; CIN-1, n = 28; CIN-2, n = 17; CIN-3, n = 19), 102 squamous cell carcinomas (SCC), 51 adenocarcinomas, and six adenosquamous cell carcinomas (adenoSCC) on immunohistochemistry.
  • In summary, DEK plays an important role in the carcinogenesis of cervical cancers, and can be helpful for early diagnosis, and is a potential therapeutic target.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Chromosomal Proteins, Non-Histone / metabolism. Oncogene Proteins / metabolism. Uterine Cervical Neoplasms / metabolism


97. Allameh A, Rasmi Y, Nasseri-Moghaddam S, Tavangar SM, Sharifi R, Sadreddini M: Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects. Cancer Epidemiol; 2009 Jul;33(1):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
  • SUBJECTS: Formalin-fixed, paraffin-embedded esophageal specimens (n=87) from patients with gastroesophageal reflux disease (GERD), Barrett's metaplasia, adenocarcinoma (ADC) and squamous cells carcinoma (SCC) were collected based on their pathological diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology


98. Nason KS, Farrow DC, Haigh G, Lee SP, Bronner MP, Rosen SN, Vaughan TL: Gastric fluid bile concentrations and risk of Barrett's esophagus. Interact Cardiovasc Thorac Surg; 2007 Jun;6(3):304-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with Barrett's esophagus are at high risk of progression to adenocarcinoma.
  • Cases (n=72) were identified by new histologically-confirmed diagnosis of specialized intestinal metaplasia (indicative of Barrett's esophagus) following upper endoscopy for refractory gastroesophageal reflux between October 1997 and September 2000.
  • Cases were compared to gastroesophageal reflux patients without specialized intestinal metaplasia (controls; n=72).

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17669852.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts
  •  go-up   go-down


99. Torres Gómez FJ, Torres Olivera FJ, Torres Gómez A: [Polypoid cystitis associated with glandular cystic cystitis]. Arch Esp Urol; 2007 Jul-Aug;60(6):692-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Polypoid cystitis and intestinal metaplasia are well-known lesions of the bladder.
  • RESULTS: Although these lesions are not neoplastic, there are evidences supporting a possible degeneration of the metaplastic epithelium to adenocarcinoma.
  • CONCLUSIONS: The diagnosis of both lesions is histological and there are not clinical tests or image studies that could enable identification of the real nature of these lesions.
  • [MeSH-minor] Aged. Cysts / pathology. Humans. Intestines / pathology. Male. Metaplasia / pathology. Polyps / pathology. Urinary Bladder / pathology. Urinary Bladder Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847746.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Samet I, Cormier B, Mowlawi H, Philippe A, Arbion F, Fétissof F: [Endometrial and endocervical lesions associated with pseudomyxoma peritonei: a case report]. Ann Pathol; 2009 Jun;29(3):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Appendiceal Neoplasms / complications. Cervix Uteri / pathology. Endometrium / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / complications. Pseudomyxoma Peritonei / etiology
  • [MeSH-minor] Appendectomy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Epithelial Cells / pathology. Female. Humans. Hysterectomy. Metaplasia. Middle Aged. Neoplasm Invasiveness. Ovariectomy






Advertisement